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A major risk factor for cardiovascular disease (CVD) is elevated low-density lipoprotein 
cholesterol (LDL-C). High-density lipoprotein (HDL) functionality can play a role in 
reducing risk for CVD by assisting in cholesterol homeostasis. Additionally, high plasma 
trimethylamine-N-oxide (TMAO) concentrations are related to increased CVD risk and 
increased atherosclerosis progression. Eggs are a rich source of dietary choline, a 
precursor for TMAO formation. Therefore, the effects of egg intake in comparison to a 
choline bitartrate supplement were explored in a young, healthy population. The aim was 
to show the benefits of egg consumption without increasing risk for CVD in young adults. 
The hypothesis was that choline from eggs would increase plasma choline concentrations 
and would not negatively increase plasma TMAO in comparison to choline bitartrate.   
 
Thirty participants (48% males; 25.6  2.3 years old; body mass index (BMI) 24.3  2.9 
kg/m2) consumed 3 eggs per day or choline bitartrate (~400 mg dietary choline in eggs 
or supplement) for 4 weeks each in a randomized crossover study, followed by a washout 
period and then allocated to the alternate treatment. Anthropometrics data, dietary 
records, and blood samples were collected at the end of each interventional arm for 
analyses.  
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When comparing treatments, no change was observed in BMI, waist circumference, blood 
pressure, plasma fasting glucose, triglycerides, creatinine, and liver enzymes. Total 
cholesterol, LDL-C, and HDL cholesterol (HDL-C) was higher, and C-reactive protein was 
lower with egg intake, with no changes in LDL-C/HDL-C ratio. Dietary total fat, cholesterol, 
selenium, and vitamin E were higher, and carbohydrates were lower as a result of egg 
consumption. For HDL functionality, egg intake resulted in higher apolipoprotein (apo) AI 
and E with no changes in apo B or paraoxonase 1 activity. Cholesterol biosynthesis was 
down regulated with egg intake at the gene expression level. Fasting plasma choline was 
increased with egg intake. Surprisingly, no difference in plasma TMAO was seen with 
treatments.  
 
Data suggest that egg intake contributes to choline availability in plasma when comparing 
to choline bitartrate supplementation, while the dietary cholesterol regulates the 
endogenous synthesis of cholesterol without negatively impacting risk for CVD in young, 
healthy individuals. 
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1.1. Introduction 
Cardiovascular disease (CVD) is considered the leading cause of death in the United 
States1. Atherosclerosis, the major cause of CVD, is characterized as a continuous lipid 
accumulation and inflammatory cells in the intima of large arteries2. This condition is 
initiated by the infiltration of the most atherogenic particle, low-density lipoprotein (LDL)3. 
When in the intima, LDL can be modified or oxidized, taken up by macrophages, and 
result in foam cell formation. If this process persists, the fibrous cap formed becomes 
susceptible to rupture, causing clinical manifestations such as acute myocardial infarction 
or sudden death2. Many other factors can contribute to the development of 
atherosclerosis. Data suggest that modifiable factors such as diet and physical activity 
can prevent the risk of CVD1. 
 
With the increasing prevalence of CVD, research has focused on dietary components and 
their associations with atherosclerosis progression. Trimethylamine-N-oxide (TMAO) is a 
metabolite studied due to its relationship with atherosclerosis risk in humans and 
atherosclerosis development in mice4. Dietary nutrients such as choline, carnitine, and 
betaine are utilized by the gut microbiota to produce trimethylamine (TMA)5. When 
circulating TMA reaches the liver, it can be oxidized by flavin monooxygenases (FMO) to 
TMAO. High concentrations of TMAO in mice have been shown to promote aortic root 
atherosclerotic plaque formation5. Consequently, TMAO enhances the expression of 
scavenger receptors (CD36 and SR-A1) responsible for the uptake of cholesterol and 
foam cell formation in macrophages4. Additionally, high concentrations of TMAO in 
plasma are associated with CVD risk in a large human cohort study4 and increase in 
 3 
platelet reactivity and thrombosis in healthy individuals6. Therefore, the increased 
awareness about consuming foods high in TMA/TMAO precursors. 
 
Dietary cholesterol has been thought to be a factor for CVD risk. With that, the 
consumption of eggs is still dubious to the general population due to its high cholesterol 
content. On the other hand, epidemiological data show no correlation between dietary 
cholesterol and CVD risk7. Besides, eggs are a great source of high quality protein, 
vitamins, minerals, and choline8. Although the Dietary Guidelines for Americans 2015-
2020 removed the daily recommendation for dietary cholesterol9, eggs are still being 
targeted due to their choline content (~130 mg per large egg)10. Choline is an essential 
nutrient that exerts various functions such as neuron development, homocysteine 
metabolism, cell-membrane signaling, and lipid transport11. Nevertheless, Americans do 
not meet the adequate intake of daily dietary choline which can lead to choline deficiency 
and result in fatty liver12. Therefore, there is an interest in exploring food sources rich in 
choline that increase choline intake and bioavailability in plasma without compromising 
metabolic functions. While choline is a precursor for TMAO, continuous research is being 
done to evaluate different sources of choline and TMAO formation.  
 
Understanding the impact of egg consumption in comparison to another choline source, 
such as a choline bitartrate supplement, helps to fill the gap in the literature and further 
explore the effects on TMAO formation. Therefore, the following study had the objective 
to assess two different sources of choline in the formation of plasma TMAO and 
bioavailability of choline. CVD risk biomarkers such as plasma lipids, lipoprotein profile, 
 4 
HDL functionality, gene expression in regard to cholesterol biosynthesis and TMAO 
metabolism, and fasting plasma choline and TMAO concentrations, were determined with 
the purpose to investigate if eggs can be incorporated into the diet of healthy, young 
adults without raising their risk for CVD. The hypothesis was that choline from eggs would 
increase plasma choline concentrations and would not negatively increase plasma TMAO 
not CVD biomarkers in comparison to choline bitartrate supplement, a free choline form.     
 5 
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2.1. Cardiovascular Disease and Lipid Metabolism 
2.1.1. Atherosclerosis 
Living a healthy lifestyle has become a great concern to the general population. With the 
increase in prevalence of the leading cause of death in the United States and worldwide, 
cardiovascular disease (CVD) is affecting one in every four Americans13. CVD involves 
conditions that affect the heart and blood vessels consequently increasing the risk of 
cardiovascular events that include heart attack and failure, stroke, and/or arrhythmia14. 
Therefore, the importance to further understand the mechanisms and treatments 
associated with CVD as well as to help diminish the continuous rise in death rate. 
 
Atherosclerosis, the major cause of CVD, characterizes by the onset of an inflammatory 
state in the arterial wall involving lipids and immune cells2. The main risk factor for 
atherogenesis is the increase in circulating cholesterol-rich lipoproteins, primarily low 
density lipoprotein (LDL)15. Briefly, LDL is sequestered by the arterial wall, where it will 
undergo modifications such as oxidation3. Consequently, resident macrophages will 
engulf these modified particles forming foam cells and then initiate an acute inflammatory 
process, which will involve secretion of pro-inflammatory cytokines that will recruit more 
monocytes to the lesion site15. The ongoing formation of foam cells with the release of 
growth factors and cytokines will lead to a fatty streak, which will eventually recruit 
vascular smooth muscle cells (VSMC) to the intima in order to form a fibrous cap16. With 
the continuous growing of this fibrous cap, the atherosclerotic plaque can rupture due to 
weakening of the cap and decrease of VSMCs, resulting in thrombus which can have a 
clinical manifestation of myocardial infarction and sudden death2. The role of LDL in 
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atherogenesis and high-density lipoprotein (HDL) in the prevention of atherosclerosis 
plaque formation via reverse cholesterol transport (RCT) is extremely important. 
 
2.1.2. Lipoproteins 
Lipoproteins carry cholesterol through circulation and play an important role in CVD and 
lipid metabolism. Epidemiological studies have shown that high LDL cholesterol (LDL-C) 
and low HDL cholesterol (HDL-C) levels are a risk factors for CVD2. Therefore, 
understanding lipoprotein metabolism helps elucidate potential therapeutics and 
biological targets for emerging pathologies, most specifically atherosclerosis.  
 
Dietary lipids, fat and cholesterol, are absorbed in the small intestine and incorporated 
into lipoproteins known as chylomicrons. When dietary fats are in the chylomicrons, they 
travel into the lymphatic system, then into circulation where they deliver lipids to 
extrahepatic tissues, primarily adipose tissue. By the action of lipoprotein lipase (LPL), 
lipids are delivered to these tissues and eventually chylomicrons will transform into 
chylomicron remnants17. Then, hepatocytes recognize chylomicron remnants due to the 
presence of apo E in these particles and they are taken by the liver either by the LDL 
receptor (LDLR) or LRP, which recognize apo E. The lipid content from chylomicron 
remnants within the liver cells along with endogenous lipids form very low-density 
lipoprotein (VLDL) particles containing apo B-100 which will be secreted into circulation. 
These particles deliver its content to adipose tissue, muscle and other tissues through the 
action of LPL, and then an intermediate density lipoprotein is formed18. After further 
processing and lipolysis, LDL is formed which can be taken up by the liver or extrahepatic 
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tissues via LDLR for cholesterol turnover or excretion. In case of elevated LDL-C, 
atherogenesis will develop where these small LDL can be oxidized and eventually 
macrophages will recognize these particles via scavenger receptor A (SRA) and/or cluster 
of differentiation 36 (CD36). Once they are taken up by macrophages present in the 
intima, an inflammatory process will start which will results in foam cell formation.  With 
this ongoing process plaque will buildup, leading to a fatty streak and a fibrous cap 
formation which can eventually rupture. The rupture results in a thrombus which can 
cause acute myocardial infarction, a major symptom of cardiovascular disease, or even 
sudden death19. 
 
Homeostasis occurs in every system of the human body. Therefore, in regards to 
lipoprotein metabolism, HDL plays a role in removing cholesterol from the extrahepatic 
tissues via RCT20. The major apolipoprotein associated with HDL is apo AI which is 
primarily synthesized in the intestines and liver. When apo AI associates with 
phospholipids, it has a discoidal shape. Apo AI is a structural protein that mediates 
transfer of cholesterol from extrahepatic tissues, such as macrophages, via ATP-binding 
cassette transporter 1 (ABCA1), as well as activates lecithin:cholesterol acyl transferase 
(LCAT)18. HDL becomes mature as more sterol cholesterol is loaded into the particle core 
and trapped by LCAT-mediated formation of cholesteryl ester, where the shape of HDL 
changes form discoidal to spherical18. This mature particle, or small HDL, is recognized 
by ATP-binding cassette subfamily G member 1 (ABCG1) due to the interaction of the 
receptor and apo AI17. While in circulation, cholesteryl esters in HDL can be transferred 
to apo B containing lipoproteins, such as VLDL and LDL, via cholesteryl ester transfer 
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protein (CETP)18. Then HDL goes to the liver where it is recognized by scavenger 
receptor class B type 1 (SR-B1), taken up and targeted for elimination through the bile.  
 
2.1.3. Dietary Fat and Cholesterol 
Diet plays an important role in health-related diseases, especially for cardiovascular 
disease (CVD) where a poor diet is a factor associated with the disease. For many years, 
the ideal nutritional lifestyle was maintaining calorie intake and energy expenditure 
equilibrium and decrease dietary fat intake21. As a results, diets low in fat and high in 
carbohydrates had been recommended in 1980, and in parallel, there was a rise in obesity 
rates in the United States21. Therefore, current changes in dietary recommendations for 
the types of fats to be consumed are based on scientific evidence, considering results in 
nutritional science research, to promote a healthy dietary pattern as seen on the Dietary 
Guidelines for Americans 2015-2020 (DGA)9.  
 
In regards to CVD the consumption of dietary fats and cholesterol has been questioned, 
and it is well established that intake of saturated fatty acids (SFA) are associated with 
CVD risk to a certain extent22. Without a doubt, trans fat has many adverse effects 
towards CVD risk such as raising LDL-C, lowering HDL-C and increasing inflammation, 
for these reasons its consumption should be limited21. Additionally, epidemiological data 
have shown that SFA intake results in an increase of LDL-C23, which is a well-known 
factor for CVD risk. In the United States the average intake of SFA is 10.7% of total 
energy24, and emerging research has been focusing on the replacement of SFA with other 
fats in order to reduce the risk for CVD. This is in accordance to the most recent DGA 
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which recommends limiting calories from saturated fats by consuming less than 10% of 
calories per day9. The idea of SFA being replaced by other macronutrients is not very well 
established, but there are different recommendations from authority agencies in regard 
to substituting SFA with polyunsaturated fatty acids (PUFA), monounsaturated fatty acids 
(MUFA), protein and carbohydrates. Nevertheless, studies have shown that substituting 
SFA with total carbohydrates increases the risk for coronary heart disease25,26, since 
refined starch and added sugar are precursors for de novo lipogenesis leading to increase 
in plasma triglycerides, another major risk factor for CVD. 
 
The fate of SFA is determined by the length of the fatty acid chain. There are three 
different chains: short chain fatty acids with 1-6 saturated carbons, medium chain fatty 
acids (MCFA) with 7-12 saturated carbons, and long chain fatty acids (LCFA) with 13 or 
more carbons that can contain one or more double bonds22. Interestingly, the substitution 
of LCFA to MCFA can affect the absorption and metabolism of these fatty acids. MCFA 
is absorbed and transported through the portal vein directly to the hepatocytes where it 
can enter the mitochondria without needing the carnitine shuttle and be utilized for fatty 
acid oxidation27. On the other hand, LCFA are absorbed via chylomicrons as previously 
described and consequently taken up by adipose tissue. In addition, LCFA require the 
carnitine shuttle system to enter the mitochondria for fatty acid oxidation27. Therefore, 
replacing LCFA in the diet to MCFA can affect these metabolic pathways, in addition 
research have suggested a possible increase satiety and energy expenditure with MCFA 
intake, which are major factors that help promote weight management.  
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Saturated fatty acids that are primarily consumed in the American diet are myristic acid 
(14:0), palmitic acid (16:0), and stearic acid (18:0)22. Interestingly, stearic acid has been 
shown to reduce LDL-C and have no negative affect on CVD risk23 because during  its 
metabolism it is converted to oleate (18:1, n-9), an monounsaturated fatty acid28. Food 
sources most common in the American diet that are high in SFA are cheese (16.5% of 
SFA intake) and milk (8.3% of SFA intake), which have not shown an association to CVD 
risk in epidemiological studies as well as meta-analyses of 26 studies when these were 
consumed22. Nevertheless, the DGA recommends reducing the intake of SFA in addition 
to consuming fat-free or low-fat dairy9. Thus, these foods high in SFA have other bioactive 
compounds with anti-oxidant and anti-inflammatory properties that may lower risk for CVD 
and are still targeted for reduced consumption strictly due to their fat content.  
 
Another dietary fat that is highly consumed in the American diet is monounsaturated fatty 
acids, where oleic acid represent 92% of MUFA consumed22. Sources of oleic acid 
include plant-based olive oil, canola oil, nuts, butter and animal sources such as meat, 
dairy and eggs29. Studies demonstrate that diets high in MUFA (>12% total calories) 
resulted in lower fat mass and blood pressure when compared to diets low in MUFA 
(≤12% total calories)30. Other researchers have found that consumption of high MUFA 
diets (>15% total calories) were associated with increased HDL-C, decreased 
triglycerides and blood pressure31, as well as body composition differences and 
reductions in weight32. The mechanism thus far to how MUFA promote cardiovascular 
health are primarily based on alteration of lipid and lipoprotein profile33. MUFA shifts fat 
catabolism as well as inactivates sterol regulatory binding protein 2 (SREBP2), an 
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important transcription factor for endogenous cholesterol production, in addition to 
increasing expression of LDL receptors in the liver by regulating acyl-CoA cholesterol 
acyltransferase when subjects consumed a diet high in oleic acid34. Therefore, food 
sources high in MUFA may promote lower risk to CVD, especially foods that contain other 
bioactive compounds. 
 
Another category of fats that has been investigated is PUFA, primarily linolenic acid (n-3) 
and linoleic acid (n-6). Meta-analysis and epidemiological studies show that substitution 
of SFA with PUFA can reduce risk for CVD 17%35 and 25%36 respectively. Furthermore, 
a systematic review investigating randomized control trials with CVD risk outcomes 
observed that the replacement of 5% energy of SFA with PUFA reduced LDL-C by 10 
mg/dL as well as total cholesterol to HDL-C ratio by 0.1637. Elderly participants without 
CVD (> 65 years old) at the start of an observational study were followed for 18 years, 
and higher plasma linoleic acid levels was associated with lower CVD mortality, also 
having high concentrations of both n-3 and n-6 PUFA showed a 54% lower mortality 
risk38. Few studies have investigated effects of linolenic acid consumption and CVD risk 
due to the fact that small amounts are found in dietary sources which is not feasible for 
SFA substitution, but growing evidence shows relationship between alpha linolenic acid 
and cardiometabolic wellness22. Consequently, substituting SFA for PUFA in the diet 
lowers the incidence of CVD and promotes cardiovascular health benefits.  
 
Cholesterol is an essential lipid molecule due to its structure and functional properties. 
Importantly, cholesterol is part of biological membranes whose purpose is to stabilize lipid 
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rafts and membrane proteins. It is also used in cellular communication in regards to nerve 
conduction, intracellular transport and endocrine signaling39. Structurally, cholesterol 
serves as a precursor for steroid hormones, vitamin D3, and cholic acid for bile acid 
synthesis40. Since cholesterol has a polar hydroxyl group, it is insoluble in water, and 
therefore carried in lipoproteins in the bloodstream. Maintenance of cholesterol 
homeostasis involves the metabolism of lipoproteins, dietary cholesterol, and de novo 
cholesterol biosynthesis which is regulated by cholesterol utilization and excretion41. 
Consequently, elevated cholesterol in serum results in health problems, primarily 
cardiovascular disease13. As a result, dietary cholesterol has been targeted as a major 
contributor to CVD risk.  
 
The main dietary cholesterol food sources include egg yolk, shrimp, beef, pork, poultry, 
cheese and butter9. Before the removal of dietary cholesterol recommendation of fewer 
than 300 mg/day from DGA9, no scientific evidence was used to support the hypothesis 
that dietary cholesterol increased plasma cholesterol and therefore increased risk for 
CVD. Now the most recent DGA states no limit for dietary cholesterol intake, but 
recommends eating as little as possible to promote a healthy eating pattern9. In addition, 
the DGA mentions that food sources of cholesterol are also high in saturated fats, which 
targets these food groups, but even though eggs are an exception there has been a 
decrease in consumption among the American population42.  
 
Notably, the hepatic cholesterol pool is made up of exogenous cholesterol coming from 
the diet and endogenous cholesterol from de novo synthesis of hepatic and/or extra-
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hepatic tissue13. Thus, case-control studies have shown no relationship between dietary 
cholesterol and coronary heart disease (CHD) risk in both men and women despite the 
difference of 16 mg/day of dietary cholesterol on a 2500 kcal diet between groups43. 
Additionally, epidemiological studies that have shown association of dietary cholesterol 
to CVD risk present confounding variables of increased saturated fat and decreased 
dietary fiber intake which significantly influence the interpretation of the data43. 
Consequently, a concrete biological explanation for dietary cholesterol consumption and 
risk for CVD is difficult since the daily cholesterol metabolism (exogenous and 
endogenous) is over 1000 mg. With that, eggs have been targeted for their dietary 
cholesterol content and for increasing risk for CVD since they contribute to one fourth of 
dietary cholesterol consumed in the American Diet44.  
 
2.2. Eggs  
2.2.1. Eggs Benefits - Nutrients 
Eggs are a high food source of dietary cholesterol, however they are also a food source 
relatively low in saturated fatty acid, rich in nutrients and vitamins, and very affordable13. 
With the idea that dietary cholesterol has a potential link to CVD risk, the consumption of 
eggs was low in the United States42 during the years 2010-2015 of the Dietary Guidelines 
for Americans (DGA). Interestingly, the most current DGA egg intake per capita increased 
in America within the last few years42. These data show that the population has become 
more aware of the benefits in eggs which include a great source of high-quality protein, 
vitamin A, E, D and B12, folate, selenium, iron and choline45. Additionally, one large egg 
has 72 kilocalories46, and is most frequently consumed for breakfast. Studies have shown 
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that eliminating eggs from a daily breakfast will result in consumption of high caloric foods 
and poor nutritional status47. Individuals that consume eggs have higher intake of vitamin 
E, D and B12, carotenoids (lutein and zeaxanthin), folate, selenium and choline47–50 as 
well as monounsaturated fatty acids51–53. Therefore, the nutrients in eggs can contribute 
to the recommended dietary allowance (RDA)54 for micronutrients in accordance to the 
DGA9, and may help prevent dietary deficit intake that may affect different diseases. 
 
The DGA recommends limiting caloric intake and focusing on nutrient-dense foods as a 
way of preventing the risk for chronic diseases such as obesity, cardiovascular disease, 
diabetes, and cancer9. In addition, the acceptable macronutrient distribution ranges for 
male and female adults are 10-35% of proteins, 45-65% of carbohydrates and 20-35% of 
total fat9. For cardiovascular disease prevention, clinical guidelines recommend lowering 
total dietary fat percentage consumption, in addition to reducing intake for saturated fatty 
acids (<10%), trans fatty acids (<1%), while monounsaturated fats and n-3 
polyunsaturated fats should account for the remainder fat calories55. In regards to dietary 
cholesterol, 2015-2020 DGA has removed the limit of <300mg/day and states that egg 
yolks are “higher in dietary cholesterol but not saturated fats”9. Eggs make a great 
affordable food to be included in the American diet as a prospective functional food. 
 
Balancing the amount of each macronutrient is important for a healthy diet. An egg is low 
in carbohydrates, and contains an average of 12g/100g of proteins and lipids45. Since 
eggs are typically consumed as a breakfast food, the low carbohydrate content45, high 
satiety index56 and protein45 are key factors in reducing appetite as well as energy intake 
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throughout the day52,57. Studies have shown that high protein intake when compared to 
carbohydrates has an impact on plasma ghrelin, a gastrointestinal peptide that helps in 
regulating appetite58. When consuming two eggs per day in comparison to oatmeal, a 
heart healthy food, for breakfast, a decrease in appetite, caloric intake, and fasting plasma 
ghrelin was observed due to the high protein and moderate carbohydrate intake (50%)52. 
Even though the glycemic index in this intervention did not differ, glycemic load was lower 
with the egg intake which lowers the consumption of carbohydrates following a breakfast 
with eggs52. Also, consuming eggs for breakfast in comparison to bagels resulted in lower 
glucose, insulin and ghrelin in adult men57. The decrease in plasma ghrelin can be 
attributed to the increase in satiety caused by proteins in eggs. Eggs have high-quality 
proteins with the highest biological value. Proteins in eggs have been shown to delay 
gastric emptying as well as lowering post-prandial ghrelin59. In addition, eggs are an 
economical source of protein that can contribute to protein in the diet.  
 
The majority of protein in eggs is mostly in the egg white46. The high-quality protein in 
eggs aid in protein synthesis and maintenance of skeletal muscle mass8. An average of 
6.3 grams of total protein are in one large egg10, which can contribute to protein functions 
as well as provide essential amino acids60. The most abundant amino acids in eggs are 
leucine, glutamic and aspartic acids, in addition to branched and aromatic amino acids. 
Egg white contains a great amount of leucine (15 grams of egg white = 1300 mg of 
leucine) which has been shown to promote a maximal anabolic response in young adults, 
therefore augmenting body mass61. Some other desirable effects of leucine include 
triggering skeletal muscle synthesis, stimulating muscle cells hypertrophy, reducing 
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muscular protein breakdown as well as reducing associated signaling pathways by 
decreasing mRNA downregulation62. Egg white proteins impact inflammation, and the 
serine proteinase inhibitor present in eggs allows proteins to be absorbed intact without 
being degraded or broken-down by trypsin in the digestive system63,64. Examples of these 
proteins include ovalbumin, ovotransferrin, ovomucin, lysozyme and avidin which can be 
highly digestible when cooked in comparison to raw protein intake64,65. Egg lysozymes is 
a promising alternative for chronic inflammatory treatment. Supplementation of 
lysozymes to a pig model of colitis induced with dextran sulfate resulted in a reduction of 
inflammation and colitis symptoms, while increasing anti-inflammatory markers such as 
interleukin 4 and transcription growth factor beta, indicating egg lysozymes as a potential 
therapeutic for this prevalent disease66. Additionally, ovotransferrin an egg yolk phosvitin, 
showed antibacterial activity by reducing inflammatory cytokines in both a mouse colitis 
model and E. coli respectively67,68. When ovalbumin is degraded, it forms an active 
peptide called ovokinin that has an effect in reducing blood pressure in hypertensive 
rats69. Also a reduction in diastolic blood pressure in healthy young adults has been 
attributed to an increase in egg consumption48. Overall, proteins present in eggs play an 
important role in muscle mass synthesis and inflammation reduction. 
 
Egg are low in saturated fatty acids and one large egg contains an average of 187 mg of 
dietary cholesterol10. Phospholipids in eggs are highly concentrated in the egg yolk. About 
1.3 grams of phospholipids which constitute about 30% of total lipids in a whole egg are 
concentrated in the egg yolk70. Glycerophospholipid phosphatidylcholine is the most 
abundant phospholipid in egg yolk (71% total phospholipid), and other phospholipids 
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include phosphatidylethanolamine (18%), lysophosphatidylcholine (3%), 
phosphatidylinositol (4%), lysophosphatidylethanolamine (1%) and the sphingolipid 
sphingomyelin (2%)71. Fatty acids can vary according to the diet, age and environment of 
the hen, but the majority are long chain saturated and monounsaturated fatty acids8. 
Egg’s phospholipids have been shown to be highly bioavailable with an absorption greater 
than 90%. Most of the phospholipids are incorporated into HDL lipoproteins instead of 
apo B containing lipoproteins or other lipids carriers72. Consumption of 3 eggs per day in 
metabolic syndrome participants results in phosphatidylethanolamine and sphingomyelin 
species in HDL particles in comparison to yolk-free alternative73. Additionally, egg intake 
increases HDL cholesterol in various others populations, as well as different amounts of 
eggs consumed51,52,74–76. Egg intake has been shown to not only increase HDL 
cholesterol, but also modulate HDL metabolism by increasing ATP-binding cassette 
transport A1, promoting anti-inflammatory activity, and resulting in larger HDL particle 
size with less atherogenic properties, which may increase anti-oxidant enzymes 
associated with HDL51,74,76,77. Most research focuses on the pro and anti-inflammatory 
outcomes related to phosphatidylcholine from eggs. In regards to anti-inflammatory 
properties, treatment and supplementation have shown positive clinical results in colitis, 
reduced inflammatory damage in arthritis and lowered tumor necrosis factor alfa in a 
neuroinflammation mouse model78–80. On the other hand, eggs are a rich source of dietary 
cholesterol, however cholesterol absorption varies among individuals81 due to cholesterol 
biosynthesis regulation in response to exogenous cholesterol51,77,82. Nevertheless, 
despite eggs being a high source of dietary cholesterol, the concern of egg consumption 
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has been shifting from its dietary cholesterol to its choline content and formation of 
atherogenic metabolite trimethylamine-N-oxide. 
 
In addition to proteins, phospholipids and cholesterol, eggs contain vitamins and minerals 
as well as carotenoids. The carotenoids present in the egg yolk, lutein and zeaxanthin, 
are known for their antioxidant properties, and their composition can also vary according 
to the hen’s diet50,83. Despite the low quantity of carotenoids in eggs, in relation to plant 
sources, egg carotenoids have shown to be more bioavailable especially in boiled versus 
scrambled eggs84. These carotenoids are carried by lipoproteins, and egg consumption 
has been shown to increase plasma lutein and zeaxanthin50,76, where lutein is accessible 
to exert a protective effect against age-related macular degeneration85,86. Lutein has 
antioxidant activity due to its double bonds that is able to quench reactive oxygen species 
and free radicals87. This activity has been shown in vitro and animal studies, as well as 
various tissues including the eye, liver and aorta 88–90. The mechanism that has been 
shown to be very protective in the eye macular oxidative damage induced by blue light91,92 
is via a singlet oxygen quenching with the free radicals resulting in unsaturation and 
resonant stabilization93. With that, one large egg contains an average of 190 mcg of total 
carotenoids, where lutein and zeaxanthin are more than 90% of the carotenoids46. Egg 
consumption has improved carotenoids status, increased dietary intake and plasma lutein 
and zeaxanthin in healthy young adults51,76, metabolic syndrome participants50, and older 
adults (>60 years of age) with altered lipid profile94. 
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Eggs provide fat-soluble vitamins and B vitamins, as well as minerals that can contribute 
to lowering the risk of diseases also due to their antioxidant activity95. In addition, nutrients 
in eggs can aid on the risk of low-nutrient intake in vulnerable populations such as 
children, pregnant women and elderly45. Minerals present in eggs include phosphorus, 
selenium, iron and zinc, where one egg has the recommended daily intake (RDI) of 16%, 
29%, 9% and 9%, respectively, of these minerals. In addition, eggs also contain 10% of 
RDI for vitamin A, D, E, K, B2, B12, biotin and pantothenic acid.96 Some minerals and 
vitamins can be fortified in eggs by enhancing the hen’s diet. Oxidative damage and 
homeostasis are regulated by the expression of antioxidant enzymes which can be 
affected by inflammation, aging, smoking and toxins96. Antioxidants can also be 
consumed in the diet that can potentially prevent reactive oxygen species damage and 
help maintain homeostasis as well as cellular functions96. Some of these natural 
antioxidants, which are also present in eggs, include vitamin E, carotenoids and some 
peptides with such properties96. Vitamin E plays an important role in reducing lipid 
peroxidation reaction due to its phenolic hydrogen radical that is donated to the lipid 
peroxyl radical, consequently becoming a more stable radical97. Consumption of eggs 
increases dietary vitamin E intake (1.1 mg per large egg) and absorption49, resulting in 
higher vitamin E in plasma which shows how eggs affect positively the bioavailability of 
fat soluble vitamins98. Addressing the contribution of egg intake to increase vitamin E is 
crucial since more than 90% of American do not meet the recommended amount of 
vitamin E for their age, sex, and health needs99. The most active form of vitamin E, -
tocopherol, is known for protecting long chain polyunsaturated fatty acids in the 
membrane against oxidation96. In addition, vitamin E is carried in the LDL and HDL where 
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they also protect against oxidation of these lipoproteins which can contribute to lowering 
risk for cardiovascular disease in both men and women100,101. Lastly, eggs are a great 
source of vitamin D (6% of daily value), especially since it is a nutrient of concern due to 
low consumption in the United States which can affects its biological functions9. Intake of 
eggs increase dietary vitamin D in healthy adults48. Even though the amount of plasma 
vitamin D concentration remains in debate, 30-70% of the American adults have low 
plasma vitamin D which is associated with cardiovascular disease, osteoporosis, cancer, 
and other diseases102,103. 
 
The most abundant protein in egg whites, ovalbumin (54%), has antioxidant properties 
due to its free thiol groups that regulate redox reactions and bind to metal ions104. 
Peptides formed from the degradation of ovalbumin by trypsin have shown antioxidant 
and angiotensin I-converting enzyme inhibition properties which can be beneficial for 
hypertension. In addition, it slowed down low density lipoprotein oxidation, an important 
factor contributing to cardiovascular disease105. The second most abundant protein in egg 
white, ovotransferrin (12%), has superoxide dismutase-like activity towards superoxide 
anions, demonstrated to be higher than ascorbate or serum albumin, and it prevents iron-
induced lipid peroxidation100. Selenium (17% of daily value) and iodine are also present 
in eggs and contribute to its antioxidant properties. Selenium is an essential mineral for 
antioxidant proteins such as glutathione peroxidase and other selenoproteins106, while 
iodine deficiency can cause excessive hydrogen peroxide due to stimulation of the thyroid 
gland100. Egg intake has shown to increase selenium intake in healthy young adults, 
therefore contributing to antioxidant properties of this mineral48,49 Consequently, the 
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proteins, vitamins and minerals in eggs have shown to play a role in disease as well as 
contribute to dietary deficiencies.  
 
2.2.2. HDL Functionality and Inflammation 
Epidemiological data suggest that HDL-C levels are inversely correlated with CVD risk 
while LDL-C is a major factor contributing to atherosclerosis development107. As 
mentioned before, HDL particles play a role in the acceptance of excessive cellular 
cholesterol from extra hepatic tissues and its transport back to the liver108. LDL is mainly 
responsible for delivering cholesterol to peripheral tissues. Nevertheless, apolipoproteins 
are emerging as better predictors for heart disease risk in comparison to lipoprotein 
cholesterol concentrations (HDL-C and LDL-C)109, and eggs have shown to play a major 
role in changing lipoprotein particle size, HDL functionality and improving inflammation. 
 
For that, it is important to further enhance HDL functionality and prevent oxidation of LDL 
particles. HDL composition, including apo AI and antioxidant enzymes such as 
paraoxonase 1 (PON1), is crucial in determining the particle’s purpose and fate107. Apo 
AI is the major structural protein in HDL, helping in cholesterol transport and homeostasis. 
In addition, apo AI has anti-inflammatory properties by inhibiting interleukin-1-beta and 
tumor necrosis factor alpha production in rheumatoid arthritis, Crohn’s disease and other 
inflammatory diseases110. HDL has anti-oxidant properties attributed to PON1 activity, as 
well as endothelial protective effects by inducing endothelial nitric oxide synthase111. 
Interestingly, studies have shown that an increase in PON1 activity is associated with 
lower risk for CVD112, consequently favoring changes in macrophage cholesterol 
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homeostasis, and resulting in increased cholesterol efflux and decreased cholesterol 
biosynthesis113. HDL is also associated with serum amyloid A (SAA), an acute phase 
protein that is secreted in response to inflammation. SAA is inversely correlated with 
PON1 because of their opposing properties114. Another biomarker of inflammation is 
advanced oxidation protein products (AOPP), an oxidation product from 
myeloperoxidases, that play a role in atherosclerosis and fatty liver diease115. For this 
reason, it is important to further understand the role of egg consumption as a dietary 
approach to raise HDL-C and improve HDL functionality in order to prevent CVD risk. 
 
2.3. Choline Metabolism 
2.3.1. Choline – Essential Nutrient 
Over two decades, choline has been recognized as an essential nutrient11. Choline is a 
water soluble nutrient that is important for various functions such as being part of the 
neurotransmitter acetylcholine, cell membrane structure for phospholipids, lipid 
transportation as part of lipoproteins composition, as well as serving in methyl-group 
metabolism for homocysteine reduction116. Choline is necessary for phospholipid 
synthesis, especially one of the major phospholipids that is phosphatidylcholine (PC) 
which itself has various important functions, in addition to lysophosphatidylcholine, 
choline plasmalogen, and sphingomyelin, all being important for membrane 
composition11. In regards to neurobiology, choline is important for fetal brain and memory 
development as well as decreasing the chances of neural tube defect117,118. In the hepatic 
tissue, PC is required as the main component for the formation and secretion of very low-
density lipoprotein119. Therefore, the liver has the ability of producing choline moiety 
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from phosphatidylethanolamine N-methyltransferase pathway120. Nevertheless, choline 
needs to be consumed through the diet and bioavailable in plasma because of its vast 
demand for various biological functions.  
 
Choline deficiency can result in fatty liver and muscle damage as signs of subclinical 
organ dysfunction120. Dietary free choline is absorbed in the intestine via choline 
transporters into the portal circulation, which is later converted to PC in liver121. Animal 
and plant sources of choline are in the form of PC, and most of PC (>90%) is primarily 
absorbed in the intestine71,122. Lipid soluble compounds from food choline sources (PC, 
sphingomyelin glycerol phosphocholine) are broken down by phospholipase D to form 
free choline,  and then absorbed into the thoracic duct where it by-passes the liver123. 
Choline can also be converted into betaine in an irreversible pathway mediated by choline 
dehydrogenase and betaine aldehyde dehydrogenase in nucleated cells124. Betaine can 
serve as methyl group donor to homocysteine and form methionine, an essential amino 
acid123, and/or serve as an osmolyte for water reabsorption in kidney tubules125. Some 
plant sources are rich in betaine (such as beets) which can spare choline requirements 
while serving as methyl donor since betaine cannot be converted to choline116. Thus far, 
choline toxicity (3.5 g/day) was determined based on the lowest level that caused adverse 
events (hypotension)126. Adequate intake (AI) for dietary choline are based on age and 
gender, or pregnancy and lactating for females, established by the United States Institute 
of Medicine’s Food and Nutrition Board in 1998126. Male and Female adults (≥ 19 years 
old) are recommended to consume 550 and 425 mg per day respectively126. Based 
on 2009–2012 National Health and Nutrition Examination Survey (NHANES; n =16,809) 
 25 
data for dietary choline intake, the average US adult population (19-30 years old) 
consumes 324 mg/day12 which is clearly below the AI for both genders. Therefore, choline 
deficiency and its symptoms can result from this low intake of dietary choline which is of 
concern for nutrition scientists and public health professionals.  
 
Dietary choline can be found in great amounts in various food sources such as dairy 
products, eggs, chicken liver, wheat germ/bran, bacon, pork loin, beef liver, shrimp, 
soybean and other legumes/vegetables123. The major interest is the bioavailability of 
either free choline or its esterified forms and their presence in plasma following a regular 
intake. Emerging research has shown that egg consumption (0, 1, 2, 3 eggs per day for 
four weeks each) increased dietary choline, where in the consumption of 2-3 eggs/day 
participants were meeting dietary choline AI, and also an increase in plasma choline was 
observed which shows high bioavailability from choline found in eggs48. In addition, when 
eggs were consumed in comparison to an oatmeal breakfast, dietary and plasma choline 
was higher with egg intake74. Unfortunately, choline has been shown to be a precursor 
for trimethylamine-N-oxide (TMAO) formation which has been related to increase in 
cardiovascular disease risk4. Fortunately, recent research shows that consuming three 
eggs per day in comparison to a choline supplement, increase dietary and plasma choline 
without increasing fasting plasma TMAO127. With that, eggs have been targeted for being 
a high source of dietary choline, besides past demonization for its cholesterol content, 
and raising risk for cardiovascular disease.  
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2.3.2. TMAO and Atherosclerosis  
Choline is also metabolized in the colon by the gut microbiota into a metabolite known as 
trimethylamine (TMA) and other methyl amines. These metabolites are absorbed in 
circulation, and presumably excreted in the urine128. Once in the blood stream, TMA can 
be further oxidized when it reaches the liver by flavin monooxygenases (FMO) to form 
TMAO129. In a large cohort study, elevated plasma TMAO was a predictor for 
cardiovascular disease risk4 which has piqued researchers interest in TMA/TMAO 
formation and its precursors.  
 
Gut microbiota composition can influence choline metabolism. The presence of the 
microbes responsible for converting choline to TMA can affect the bioavailability of dietary 
choline. How the colonization of these bacteria occur remains unknown, but it is based 
on factors such as host genotype and diet. Nine strains of bacteria, from the phyla 
Firmicutes and Proteobacteria130, have been identified for metabolizing choline to TMA. 
Formation of TMA can also be from carnitine, betaine, ergothioneine and TMAO124. L-
carnitine can be found in red meat and dairy products131. Carnitine plays an important 
role in the transport of long chain fatty acids from cytosol to mitochondria, and half of the 
carnitine consumed in the diet is absorbed in the intestines while the other part is 
metabolized by the gut microbiota to form TMA132. Betaine is highly concentrated in 
spinach, wheat germ and wheat bran123, and it can also be formed from reduction 
reactions of choline or L-carnitine leading to the formation of TMA. Another pathway is 
demethylation of betaine to form dimethylglycine followed by decarboxylation to generate 
TMA124. Thirdly, ergothioneine is derivative of histidine and it cannot be synthesized by 
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mammals, and foods containing ergothioneine include mushrooms, meat, and some 
beans133. The role of ergothioneine in humans is not known, and its degradation also 
results in the formation of TMA124. Marine fishes contain high amounts of TMAO (3 mg/g), 
and 50% is absorbed by the body and eventually secreted in the urine, while the 
remainder is reduced to TMA by the gut microbiota134,135. One very important factor that 
contributes to TMA metabolism is diet, and individuals that consumed a Western Diet 
usually produce 50 mg of TMA/day from the action of the microbiota124. TMA is a 
metabolic waste secreted in the urine136, therefore, research has been focusing on TMAO 
since most of TMA  that is not secreted is converted to TMAO, a more stable metabolite 
in plasma. 
 
TMAO has varying biological properties across species and tissues. In humans, TMAO 
plays a role in kidney function to destabilize the effects of urea137, it helps protein structure 
stability, and favors protein folding by inhibiting endoplasmic reticulum stress138. Plasma 
levels of TMAO are influenced by diet, gut microbiota composition, kidney function, and 
activity and genotype of FMOs139. Formation of TMAO happens primarily in the 
hepatocytes by FMO3, which is ten times more active towards TMA than other FMOs129. 
Other isoforms of FMO are present in other organs such as FMO1 in both the liver and 
kidney that can also contribute to TMAO production140. FMO3 functions in glucose and 
cholesterol metabolism, where its activity is up/downregulated by sexual hormones or 
diminished due to single nucleotide polymorphisms. Increased gene expression of FMO3 
in both human and animal cell models has resulted in an increased lipogenesis as well 
as increased glucose secretion mediated by pathways of peroxisome proliferator-
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activated receptor alpha and Kruppel-like factor 15, suggesting the role of FMO3 in 
regulating lipid and glucose homeostasis141. Since FMO3 is also regulated by hormones, 
higher expression levels are seen in females because testosterone in males represses 
FMO3 activity and expression140. Another key regulator of FMO3 is farnesoid X receptor 
(FXR), and treatment with FXR agonist and cholic acid (bile acid) resulted in increased 
expression of FMO3142. Additionally, knockdown of FMO3 in animal cells has resulted in 
increased ER stress and inflammation. This mechanism is due to a damping of liver X 
receptor activation which has an effect on cholesterol balance, therefore showing that the 
TMA/FMO3/TMAO pathway is an important pathway regarding inflammation and lipid 
homeostasis129. Lastly, FMO3 is suppressed by insulin, and increased expression is seen 
in obese and insulin resistant humans and animals143. Consequently, TMAO formation 
can play a major role in increasing risk for CVD and also development of metabolic 
dysfunctions. 
 
With that, high levels of TMAO in mice have been shown to increase expression of 
scavenger receptors, CD-36 and SR-A1, responsible for initiating the atherosclerosis 
process4. Also a decrease in ABCA1 expression in murine macrophages suggested 
TMAO as a pro-atherosclerotic metabolite for foam cell formation144. Additionally, high 
concentrations of plasma TMAO, choline and betaine have been predictors for coronary 
heart disease in humans, and TMAO levels are related to greater aortic lesions area in 
animals4. Therefore, once more eggs are targeted for raising risk for CVD, but this time 
because they are high in dietary choline. 
 
 29 
2.3.3. Eggs and Choline 
Since eggs are high in dietary choline (130 mg per large egg)10, a contributor for TMAO 
formation and elevated plasma TMAO is associated with increased risk for heart disease, 
egg consumption concerns the population in regards to CVD risk. When six healthy 
individuals consumed an increasing dose of egg yolk (0, 1, 2, 4, or 6 egg yolks) for 
breakfast, there was an increase in plasma TMAO within 6-8 hours of egg consumption 
which after 24hrs returned to base levels. Additionally, urine TMAO also increased within 
the 24hrs period after the egg yolk breakfast, which indicates that 11-15% of dietary 
choline is converted to TMAO, but it clears after a period of 24hrs. In this acute model 
design, there was a TMAO variability within individuals due to the fact that there is a 
difference in gut microbiota composition among people, as well as FMO3 activity, 
especially between genders145. Another study addressing increasing doses of egg intake 
(0, 1, 2, 3 eggs per day for 4 weeks each) found no changes in fasting plasma TMAO with 
increasing doses, on the contrary there was an increase in plasma choline48. Similarly, 
when comparing 2 eggs per day versus an oatmeal breakfast, fasting TMAO remains 
unchanged while plasma choline is higher with the egg consumption74. Since free choline 
and choline esters are absorbed differently146,147, a free choline source such as choline 
bitartrate supplement resulted in an increase in fasting plasma TMAO in healthy 
individuals in addition to an enhancement in platelet aggregation6. In that case, the 
optimal egg intake of 3 eggs per day previous determined by DiMarco et al.48 that 
increased plasma choline and not raised risk for CVD was a rationale for an intervention 
comparing choline bitartrate supplementation. In order to address the gap in the literature, 
in comparison to choline bitartrate supplementation, eggs increased fasting plasma 
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choline without increasing plasma TMAO, and no difference in LDL-C/HDL-C ratio was 
seen while the cholesterol biosynthesis pathway was downregulated49,51. For this, it is 
safe to say that eggs can be included to the diet of healthy individuals. 
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3.1. Background 
Eggs are one of the main source of dietary cholesterol for Americans47. Even though the 
latest Dietary Guidelines for Americans has removed the dietary cholesterol limit 
recommendation of < 300 mg/day9, people are still concerned about eating eggs. Eggs 
are not only a rich source of dietary cholesterol but other nutrients such as 
polyunsaturated fat, folate, vitamins A and E47. Additionally, carotenoids in eggs have 
shown to elevate concentrations in plasma when consuming eggs at an increasing 
dosage(0, 1, 2, or 3 eggs per day)76, or along with a carbohydrate-restricted diet50. These 
carotenoids, lutein and zeaxanthin, are important antioxidants protecting against age-
related macular degeneration45. Eggs are also a rich source of high quality protein, which 
can help promote satiety throughout the day in comparison to a heart healthy breakfast 
such as oatmeal52. Nevertheless, eggs are a great source of dietary choline, an essential 
nutrient in the American diet11. Choline has many biological functions that can help 
promote organ function and overall health.  
 
Another concern regarding egg consumption is due to its possible negative effects on 
plasma lipids, body mass index, and liver enzymes. However, studies have shown 
favorable plasma changes caused by egg intake without increasing biomarkers for 
cardiovascular disease (CVD). When metabolic syndrome individuals were consuming 3 
eggs per day as part of a carbohydrate-restricted diet, fasting plasma triglycerides 
decreased for a period of 12 weeks along with favorable changes in parameters of 
metabolic syndrome75. On the other hand, healthy individuals consuming increasing 
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dosage of eggs per day48 or 2 eggs versus oatmeal for breakfast52 showed no changes 
in fasting plasma triglycerides, glucose, nor liver enzymes.  
 
Research is still being done to show that there is no relationship between dietary 
cholesterol intake and plasma cholesterol7, so it is important to evaluate and further 
support this hypothesis. Previous studies show that egg intake, increased total 
cholesterol52 and LDL-C48, while increasing HDL-C, and observed no changes in LDL-
C/HDL-C ratio. This ratio is established as a well-predictor of CVD risk, where a ratio > 
2.5 indicates that an individual has greater chance of developing CVD148.  
 
We were interested in evaluating the effects of dietary choline from eggs in comparison 
to choline from a supplement in order to test the outcome on CVD risk biomarkers. For 
that purpose, we used these two choline sources to primarily focus on choline metabolism 
and trimethylamine-N-oxide (TMAO) formation since it has been previously shown that 
elevated plasma TMAO is a predictor of CVD4. Therefore, we hypothesized that intake of 
3 eggs per day would result in high dietary nutrients present in eggs, increase in HDL-C 
and no change in LDL-C/HDL-C in comparison to same amount of choline in a dietary 
supplement (choline bitartrate) in young healthy population. 
 
3.2. Materials and Methods  
3.2.1. Participant Recruitment and Screening 
To evaluate our hypothesis, we recruited 30 healthy men and women considering the 
inclusion criteria 18-30 years old, body mass index (BMI) of 18.5 to 29.9 kg/m2, blood 
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pressure (BP) ≤ 140/90 mm Hg (average of three readings), healthy biochemical plasma 
parameters (fasting glucose ≤ 126 mg/dL, total cholesterol (TC) ≤ 240 mg/dL, triglycerides 
(TG) ≤ 150 mg/dL, creatinine (CREA) (0.5-0.9 mg/dL for females or 0.7-1.2 mg/dL for 
males) who were willing to consume either 3 eggs per day or 1 ½ tablets for four weeks 
each. The exclusion criteria were current or past liver disease, renal disease, diabetes, 
history of stroke, cancer, any severe infectious diseases and/or heart diseases; taking 
glucose or TG lowering medications or supplements; allergy to eggs or components of 
choline bitartrate supplement, vegan or vegetarian; taking choline supplements; pregnant 
or lactating; and taken antibiotics in the previous month. The protocols used for this 
intervention were previously approved by the University of Connecticut Institutional 
Review Board (protocol #H16-194), and participants gave consent prior to screening 
process. This clinical trial is registered at clinicaltrials.gov, trial #NTC03142763.  
 
The screening process included explanation of consent form and answering questions 
about study design and intervention. Anthropometrics data was assessed during 
screening such as blood pressure measurements (3 readings when the participants were 
sitting down with one minute in between each reading), height, weight, and waist 
circumference (3 measurements using a flexible tape above the iliac bone directly on the 
skin). Afterwards, participants were asked for a 12-hour fasting blood sample for posterior 
analysis of plasma glucose and lipids using an automated spectrophotometer (Cobas 
c111, Roche Diagnosis, Indianapolis, IN, USA). Participants were also instructed on how 
to complete dietary records during the intervention. In addition, they were asked to 
consume 3 eggs for breakfast or take choline supplement (1 ½ tablet) that were given 
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during the respective interventional arm with their first meal, preferably in the morning to 
keep consistency among participants. Researchers also asked subjects to maintain a 
normal exercise routine throughout the intervention (monitored by exercise records) and 
avoid or abstain from consuming foods high in dietary choline and its derivatives (e.g. 
betaine) as presented on Table 1. Researchers purchased eggs (grade A, large white) 
from a regional supermarket (Big Y, CT, USA), while supplements were purchased from 
Best Naturals, where each tablet provided 265 mg of choline. In order to match the 
amount of dietary choline in eggs (~ 390 mg), participants had to consume 1 ½ tablets (~ 
397.5 mg). In regard to eggs preparation, no instructions were given to the participants; 
however, they were allowed to consume only the eggs provided by the researchers. 
 
TABLE 1 
Foods containing choline and betaine to be avoided or consistently consumed during 
study based on participants common food choices (adapted from Zeisel et al., 2003123) 
Foods Total Choline (mg/100g food) Total Betaine (mg/100g food) 
Bacon 124.89 3.14 
Pork Loin 102.76 1.39 
Pretzel 38.40 236.45 
Shrimp 70.60 218.74 
Spinach, cooked 24.78 645.06 
Spinach, raw 22.08 599.81 
Wheat Bread 26.53 201.41 
Total choline is the sum of choline, phosphocholine, glycerophosphocholine, phosphatidylcholine, and 
sphingomyelin 
 
Based on standard deviation from previous studies where changes in plasma choline 
were observed following consumption of 3 eggs per day for four weeks48, this study is 
powered to detect a 7% and 25% difference in HDL-C and plasma choline48 respectively, 
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at 80% power, with significance two-sided at level of  = 0.05. Therefore, we estimated 
that 25 participants would be sufficient to observe differences between intervention 
groups. Thirty participants were enrolled to allow for attrition and because there is a 
known intra individual variability of plasma TMAO in humans, 5 additional participants 
were enrolled. 
 
3.2.2. Experimental Design  
This was a 13-week crossover dietary intervention (Figure 1), where enrolled participants 
started with a two-week washout period. During washout periods, participants were not 
allowed to consume any eggs or egg-based food (e.g. quiche) for the remainder of 9 
weeks except during the eggs arm of the intervention. They were asked to fill out 3-day 
dietary and exercise records (2-week days non-consecutive and 1 weekend day). 
Subjects were then randomized by a computer software (A: eggs, B: choline) where a 
letter was assigned to each participant to determine who would start with the egg 
intervention versus the choline bitartrate supplementation.  
 
For visit 1, researchers collected diet and exercise records, assessed anthropometrics, 
and 40mL of fasting blood into ethylenediaminetetraacetic acid (EDTA)-coated vacutainer 
tubes. Participants were then given enough eggs for a week along with a compliance 
sheets to be filled out (self-reported compliance). They were required to come to the 
research center every week to pick-up more eggs and return that week’s compliance 
sheet. In case of less than 80% of compliance, participants were removed from the study. 
On the other hand, subjects that started on the choline bitartrate supplement were given 
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enough tablets for 30 days and instructed to take 1 ½ tablet (already split in half by 
researcher) every day for 4 weeks.  
 
At the end of the first arm, visit 2, records and anthropometrics data were collected, and 
80 mL of fasting blood sample was drawn from the participant. Participants then went 
through another washout period of 3 weeks and the same instructions for the first washout 
period were given, and then they returned for visit 3 (similar to visit 1) for data collection. 
Subjects were then assigned to alternate treatments, finishing the study with visit 4 and 
data collection corresponding to visit 2 assessments.  
 
 
 
 
 
 
 
 
 
FIGURE 1 
Crossover 13-week study time line for dietary intervention 
 
3.2.3. Dietary Records 
Once enrolled, researchers instructed participants how to fill out dietary records. They 
were asked to complete 3-day dietary and exercise records during each arm of the 
Week:    0          1          2      3      4      5      6          7         8         9     10     11     12    13 
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Visit 1 Visit 2 Visit 3 Visit 4 Screening 
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intervention. Subjects were asked to choose two non-consecutive week days and one 
weekend day during the week prior to their visit (visit 2 or visit 4). Diet records were used 
to evaluate the consistency of their diet throughout the intervention to assure researchers 
that no dietary patterns were changed besides the consumption of eggs or choline. Since 
these treatments where not isocaloric, participants were allowed to substitute the eggs 
for breakfast to whatever they chose without researcher’s recommendations. This was a 
dietary lifestyle intervention; therefore, no eating advice was given. The main purpose 
was to evaluate the difference in having either of these dietary choline sources and the 
relationship between dietary choline intake and cardiovascular disease risk.  
 
During each visit, the diet records were carefully evaluated to assure the consistency and 
accuracy of the entered data in front of the participants in case any questions needed to 
be answered about entered values. Using Nutrition Data Systems for Research Software 
(2016), developed by the Nutrition Coordinating Center at the University of Minnesota 
(Minneapolis, MN, USA), diet records were analyzed. This software allows researchers 
to obtain daily average of macro and micronutrients, food groups, and other nutrients of 
interest. In addition, an analysis of the meal was performed to obtain the average of 
nutrients consumed for breakfast instead of the entire day since participants were 
instructed to consume dietary choline during breakfast. 
 
3.2.4. Anthropometrics and Plasma Biochemical Parameters 
During all visits, anthropometrics data and fasting blood samples were collected for 
posterior analyses. For weight measurement, an electronic scale was used to the nearest 
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0.1 kg. Participants were asked to wear light clothes, empty pockets and remove shoes 
during each visit to ensure consistent measurements throughout study without conflicting 
factors. Subjects were then asked to step on a standing stadiometer to measure height 
to the nearest 0.5 cm. With both of these parameters body mass index (BMI) was 
calculated (kg/m2). In order to assess central adiposity, waist circumference was 
measured by placing a flexible measuring tape directly on the skin of the participants, 
above the iliac crest to the nearest 0.5 cm, and an average of three measurements was 
recorded. Blood pressure was also monitored throughout the intervention for these 
participants. They were asked to sit quietly with feet flat on the ground for about 5 minutes 
before measuring the blood pressure using a portable automatic blood pressure cuff 
(Omron HEM 7320-Z), in which an average of 3 readings were recorded with a minute 
between each reading.  
 
For blood samples, subjects were asked to fast for 12 hours prior to each visit and drink 
only water before coming to the department for a blood draw. Using common phlebotomy 
procedures, blood was drawn from the median cubital vein into an EDTA-coated or serum 
separator (SS) with silica clot activator vacutainer tubes. During visit 1 or 3 about 30 mL 
of plasma and 10 mL of serum were collected, while visit 2 or 4 about 70 mL of plasma 
and 10 mL of serum were obtained from each participant. The EDTA tubes were inverted 
a couple of times and put on ice for posterior centrifugation. The SS tubes were allowed 
to clot for 30 minutes at room temperature prior to centrifugation. Tubes were balanced 
and centrifuged at 2000 x g for 20 minutes. Plasma and serum were aliquoted into 1.5 
mL cryovial tubes and stored at -80ºC for posterior analysis.  
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After centrifugation, 500 L of plasma were aliquoted into a cuvette, and using an 
automated spectrophotometer (Cobas C111, Roche Diagnostics, Indianapolis, IN, USA), 
plasma glucose (mg/dL), triglycerides (mg/dL), total cholesterol (mg/dL), high-density 
lipoprotein cholesterol (HDL-C) (mg/dL), alanine aminotransferase (ALT) (mg/dL) and 
aspartate aminotransferase (AST) (mg/dL), C-reactive protein (CRP) (mg/dL) and 
creatinine (mg/dL) were measured. To calculate low-density lipoprotein cholesterol (LDL-
C) the Friedewald equation was used149. LDL-C/HDL-C ratio was also calculated as a 
biomarker for cardiovascular disease risk. Creatinine values were used in the Modification 
of Diet in Renal Disease formula150 to calculate estimated glomerular filtration rate as a 
biomarker of renal function for these participants.  
 
3.2.5. Statistical Analysis  
Variables were analyzed using Student t Test comparing the end of egg intake versus 
choline bitartrate supplementation, as well as between baseline and end of each 
treatment. Positive outcomes were used to assess for correlation using Pearson’s 
correlation. Grubbs’ test was used to compute for outliers due to variability between 
participants. All statistical analyses were done using SPSS for Mac, version 25 (IBM 
Corporation). Level of significance was set at p < 0.05. 
 
3.3. Results  
3.3.1. Baseline Characteristics  
Thirty-five individuals were assessed for eligibility and thirty satisfied the inclusion criteria. 
Participants were enrolled on January 2017 (n=30) for this dietary intervention and 
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randomly distributed to eggs (n=15) or choline bitartrate supplement (n=15) for 4 weeks. 
Due to personal reasons, one participant dropped out during the first phase of the study 
while in the eggs arm (Figure 2). After 3 weeks, they were crossed over to the alternate 
treatment. Endpoint data was collected from twenty-nine participants and analyzed for all 
variables49.  
 
FIGURE 2 
Flowchart of the 13-week crossover study when comparing egg versus choline bitartrate 
intake in young, healthy individuals 
 
Baseline anthropometrics (BMI and waist circumference), blood pressure, plasma fasting 
lipids, glucose, estimated glomerular filtration rate (eGFR) are shown on Table 2, as well 
as gender and age. In addition, baseline differences between sex were evaluated, shown 
on Table 2. Participants were homogeneously distributed based on gender, age and BMI. 
On the other hand, waist circumference (p=0.009) and eGFR (p=0.001) were lower, while 
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systolic blood pressure (p=0.001) and fasting plasma glucose (p=0.003) were higher in 
females when compared to males. 
 
TABLE 2 
Baseline characteristics of young, healthy men and women (n=30) participating in a 13-
week crossover intervention with egg versus choline bitartrate supplement intake for 4 
weeks each49,51 
Parameters Total Female Male p-value 
Gender (%) - 52% 48% 0.910 
Age (years) 25.6  2.3 25.8 ± 1.9 25.2 ± 2.8 0.679 
BMI (kg/m2) 24.3  2.9 23.2 ± 2.5 24.4 ± 6.0 0.498 
Waist circumference (cm) 86.9  7.1 83.5 ± 4.7 89.8 ± 7.3 0.009 
Systolic blood pressure (mmHg) 108.9  10.9 103.1 ± 9.34 116.0 ± 8.9 0.001 
Diastolic blood pressure 
(mmHg) 
70.2  7.2 68.7 ± 6.17 70.3 ± 7.5 0.387 
Glucose (mg/dL) 92.7  5.0 90.8 ± 4.6 95.5 ± 3.6 0.003 
Triglycerides (mg/dL) 66.1  33.3 64.3 ± 27.1 70.3 ± 41.0 0.640 
Total cholesterol (mg/dL) 163.7  29.3 166.6 ± 30.66 159.9 ± 29.6 0.561 
HDL-C (mg/dL) 69.9  10.0 70.81 ± 11.9 68.46 ± 7.7 0.545 
LDL-C (mg/dL) 80.6  25.2 82.89 ± 26.5 77.40 ± 25.3 0.576 
LDL-C/HDL-C ratio 1.2  0.4 1.20 ± 0.4 1.16 ± 0.4 0.814 
eGFR (mL/min) 98.0  14.1 94.98 ± 14.6 99.39 ± 10.9 0.001 
Values are presented as mean  SD 
 
3.3.2. Dietary Records Analyses 
Based on self-reported compliance, which was assessed weekly during both 
interventions, an overall of 98% compliance was observed among participants. When 
comparing egg intake versus choline bitartrate supplement no difference in total energy 
 43 
intake and protein was observed. On the contrary, total percent fat intake (p=0.001), 
dietary cholesterol (p=0.001), selenium (p=0.001), vitamin E (p=0.026) saturated fat 
(p=0.001), monounsaturated fat (p=0.001), lutein and zeaxanthin (p=0.018) were higher 
in the eggs group. While total percent of carbohydrate (p=0.001), dietary fiber (p=0.001), 
folate (p=0.020), and glycemic load (p=0.001) were lower during the eggs intervention.  
 
TABLE 3 
Dietary record of healthy, young population (n=29) at the end of each intervention arm, 
egg versus choline supplement intake for 4 weeks each49,51  
Nutrient Eggs Choline p-value 
Energy (kcal/day) 1771.38  376.30 1841.66  423.19 0.386 
Protein (%) 23.05  6.90 20.39  9.01 0.110 
Fat (%) 40.14  7.57 32.14  8.81 0.001 
Carbohydrate (%) 34.53  8.81 45.02  11.30 0.001 
Total Fiber (g/day) 15.40  7.05 20.16  6.54 0.001 
Glycemic Load 79.93  29.08 110.52  42.99 0.001 
Cholesterol (mg/day) 746.93  100.69 198.72  68.32 0.001 
Selenium (mcg/day) 138.49  33.71 110.52  28.01 0.001 
Choline (mg/day) 696.65  96.95 690.91  96.99 0.745 
Vitamin D (µg/day) 6.24  2.44 5.71  5.28 0.548 
Vitamin E (IU) 13.38  6.63 11.17  5.37 0.026 
Betaine (mg/day) 107.34 72.19 135.99  75.65 0.087 
Folate (mcg/day) 322.41  95.74 390.52  160.79 0.020 
Saturated Fat (%) 13.44  4.46 10.91  3.58 0.001 
Monounsaturated Fat (g) 29.44  8.84 22.42  7.68 0.001 
Polyunsaturated Fat (g) 16.09  6.48 15.72  5.97 0.809 
Lutein + Zeaxanthin(μg) 1474.34  724.72 1115.41  746.15 0.018 
Values are presented as mean  SD 
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Since participants were advised to consume both eggs and choline bitartrate supplement 
for breakfast, macronutrients differences were evaluated. Higher total fat (p=0.001) and 
lower carbohydrate (p=0.001) intake was observed, while total protein (p=0.056) intake 
trended to be higher in the eggs group for breakfast. 
 
FIGURE 3 
Dietary macronutrient intake during breakfast. Percentages of fat (black bar), 
carbohydrates (Carbs; gray bar), and protein (Prot; white bar) after consuming three eggs 
per day versus choline bitartrate supplement for 4 weeks each. Values are presented as 
means  standard deviation for 29 young, healthy men and women. Bar with superscripts 
differ at p < 0.05 as determined by paired Student’s t test analysis. *p < 0.05 between 
interventions; NS = not significant considering p < 0.0549 
 
Analyses of daily food group consumption during the interventions were also evaluated 
with dietary records. There were no significant differences between beef, poultry, fish, 
pork, dairy, total vegetables, nuts and seeds when comparing egg intake versus choline 
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supplementation. The only differences observed was in legumes (p=0.014) intake, which 
was lower in the eggs group when compared to choline bitartrate intake (Table 4).  
 
TABLE 4 
Portion of daily consumption of number of servings in beef, poultry, fish, dairy, total 
vegetables, legumes, and nuts and seeds, during the eggs and the choline bitartrate 
dietary supplement periods in healthy, young participants (n =29)49   
Food Group Eggs Choline p-value 
Beef 0.95  1.14 0.96  1.35 0.972 
Poultry 2.96  2.79 3.04  2.80 0.875 
Fish 0.39  1.36 0.66  1.26 0.227 
Pork 0.63  1.83 0.47  1.70 0.346 
Dairy 1.52  0.87 1.87  1.22 0.148 
Total Vegetables 2.40  1.52 2.80  1.34 0.217 
Legumes 0.09  0.24 0.28  0.36 0.014 
Nuts and Seeds 0.96  1.57 0.83  1.20 0.587 
Values are presented as mean  SD 
 
3.3.3. Anthropometrics and Plasma Biochemical Parameters  
When comparing egg consumption as opposed to choline bitartrate supplementation, no 
changes were observed among anthropometrics measurements (BMI and blood pressure 
– systolic and diastolic), fasting plasma glucose, creatinine, eGFR, and triglycerides. As 
expected, total cholesterol was higher (p=0.040) during egg consumption, as well as HDL-
C (p=0.030) and LDL-C (p=0.049), and no changes observed in LDL-C/HDL-C ratio 
(p=0.775). As a measurement of low-grade inflammation, plasma C-reactive protein 
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(CRP) was used, and egg consumption showed lower CRP (p=0.046) in comparison to 
choline bitartrate intake.  
 
TABLE 5 
Anthropometrics measures and fasting plasma biochemical parameters for participants  
(n=29) at the end of each intervention arm, three egg versus choline bitartrate supplement 
intake for 4 weeks each51 
Parameters Eggs Choline p-value 
BMI (kg/m2) 24.1 ± 2.8 24.0 ± 2.60 0.347 
Systolic Blood Pressure (mm Hg) 108.1 ± 10.7 108.9 ± 10.9 0.604 
Diastolic Blood Pressure (mm Hg) 68.8 ± 7.7 68.8 ± 6.3 0.939 
Glucose (mg/dL) 92.3 ± 6.0 90.9 ± 5.7 0.226 
Creatinine (mg/dL) 0.85 ± 0.11 0.86 ± 0.13 0.415 
eGFR (mL/min) 100.6 ± 12.3 99.5 ± 12.9 0.553 
Triglycerides (mg/dL) 69.6 ± 29.5 73.6 ± 36.0 0.355 
Total Cholesterol (mg/dL) 172.6 ± 35.8 162.7 ± 30.7 0.040 
HDL-C (mg/dL) 61.0 ± 16.0 57.0 ± 14.3 0.030 
LDL-C (mg/dL) 97.7 ± 31.7 90.9 ± 26.3 0.049 
LDL-C/HDL-C 1.72 ± 0.72 1.70 ± 0.67 0.775 
C-reactive Protein (mg/dL) 0.18 ± 0.37 0.32 ± 0.59 0.046 
 Values are presented as mean  SD. Student’s t test was used to determine statistical significance 
 
Liver enzymes were also measured as important biomarkers for hepatic inflammation 
(Figure 4). Interestingly, there were no differences between interventions, egg intake 
versus choline bitartrate supplementation for aspartate amino transferase (AST) 
(p=0.214) and alanine amino transferase (ALT) (p=0.653). As expected, no differences 
were found between baselines for AST (p=0.123) and ALT (p=0.275) followed by the 
washout periods. On the other hand, choline bitartrate supplementation increased AST 
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(p=0.028) and showed a trend in increasing ALT (p=0.072) (Figure 4) in these young, 
healthy individuals. 
 
 
FIGURE 4 
Plasma aspartate amino transferase (AST) and alanine amino transferase (ALT) for 
baseline and end of each dietary intervention for 13-week crossover study assessing the 
effects of consuming three eggs versus choline bitartrate supplementation per day for 4 
weeks each. Values are presented as means  standard deviation for 29 young, healthy 
men and women. Bar with superscripts differ at p < 0.05 as determined by paired 
Student’s t test analysis. *p < 0.05 between interventions 
 
We also evaluated Pearson’s correlation between dietary cholesterol intake and total 
plasma cholesterol during the egg intervention. Since one large white egg contains an 
average of 187 mg of dietary cholesterol (based on NDSR data), consuming three eggs 
per day exacerbated the recommendation. As expected, there was no correlation 
(p=0.701) between dietary cholesterol (mg/day) and plasma total cholesterol (mg/dL) 
when participants were consuming 3 eggs per day for four weeks.  
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FIGURE 5 
Pearson’s correlation graph between dietary cholesterol (mg/day) and plasma total 
cholesterol (mg/dL) for participants (n=29) consuming three eggs per day for 4 weeks 
 
3.4. Discussion 
3.4.1. Baseline Characteristics  
With the removal of dietary cholesterol recommendation of 300 mg per day from the most 
recent Dietary Guidelines for Americans (DGA)9, the consumption of eggs remain a 
concern publicly in the United States. It is not known if this change in the DGA has caused 
an increase in egg consumption of about 9% from 2015 to 2017151. Additionally, data 
supports that egg consumption does not increase biomarkers of cardiovascular disease 
(CVD) risk in clinical trials conducted in various populations48,53,75. The spotlight has been 
brought on eggs regarding its dietary choline content and its relationship with 
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atherosclerotic metabolite trimethylamine-N-oxide (TMAO)4. Therefore, this study had the 
purpose to further investigate in a dietary lifestyle intervention two sources of dietary 
choline on risk factor for CVD and cholesterol metabolism in a young, healthy population.  
 
The best study design for a dietary intervention is a crossover randomized controlled 
trial152, where participants are their own control since each individual is different in  
regards to metabolism, the main interest of this study. Therefore, looking at baseline 
characteristics, these participants as a total fall within the young adult age range, with a 
healthy mean BMI, normal blood pressure, as well as fasting glucose and plasma lipids. 
When considering healthy individuals, this means that they don’t meet the criterion for 
metabolic syndrome, obesity, diabetic, or hyperlipidemia. Additionally, these participants 
had a functional kidney which was evaluated by plasma creatinine in order to calculate 
the estimated glomerular filtration rate (eGFR). On the other hand, as expected, there 
were significant differences in baseline characteristics in waist circumference and eGFR 
when comparing genders. Surprisingly and randomly, females had higher systolic blood 
pressure and fasting plasma glucose then males at baseline, but they were still within the 
parameters for healthy adults.   
 
3.4.2. Dietary Records Analyses 
Compliance was assessed based on self-reported questionnaires. Participants were 
given a weekly sheet to complete for the daily intake of eggs and choline bitartrate 
supplement during its respective interventional period. Since this was a dietary 
intervention, the dietary records collected during each treatment were used for analysis. 
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Participants were asked to complete a two non-consecutive week day and one weekend 
day in order to guarantee consistency and average of daily nutrient consumption. As a 
lifestyle dietary intervention, no advice was given on what foods to eat. Participants 
voluntarily adapted to the treatments, and no difference in total caloric intake was 
observed between eggs and choline bitartrate consumption. This is interesting, because 
it shows that the total energy intake didn’t change between interventions, even though 
each large egg contains 70 kcal46 while choline bitartrate supplement has no energy 
source. In this case, participants were adapting their diets voluntarily to accommodate 
their energy needs during the supplement phase.  
 
Interestingly, no change in total protein intake was observed between each intervention. 
It was expected that during the egg consumption participants total protein intake would 
be higher since eggs are a source of high quality protein8. For this reason, consumption 
of food groups was evaluated, and no difference was observed. Consequently, individuals 
were consuming protein from other sources that were not beef and poultry since 
consumptions rates of these protein sources also remained unchanged among 
treatments. Since participants were advised to consume the eggs for breakfast and take 
the choline bitartrate supplement with their first meal, macronutrients intake for the 
morning (breakfast) period was evaluated. The protein intake was still not significantly 
different, but it trended to be higher during breakfast possibly due to the egg-protein. 
Therefore, throughout the day participants were choosing plant-based proteins such as 
legumes, since that was the only food group significantly different in the daily dietary 
values. 
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As expected, fat and cholesterol intake were higher with the egg intake. This is due to fat 
(5 grams per egg) and cholesterol (180 mg cholesterol per egg) content in eggs10. Dietary 
cholesterol has been thought to be associated with increase in plasma total cholesterol, 
but previous studies with egg intake48,51–53,75 have not seen such association which will 
be further discussed in the following section. Different types of fat play a major role in 
disease risk23, and understanding the influence of dietary fats in CVD is essential. Diet is 
an important modifiable factor that can impact CVD risk and atherosclerosis 
progression153. Mediterranean style diets have many beneficial effects because of the 
high consumption of fruits, vegetables, and other foods that have low glycemic index154. 
In this aspect, in addition to being low in glycemic index, eggs are also a satiating food 
which can contribute to low caloric intake155. For this study, differences in saturated, 
monounsaturated and polyunsaturated fat were further evaluated. 
 
First, eggs contain 1.6 grams saturated fat (SFA) per large egg8, and it is of concern due 
to evidence showing that diets high in SFA can increase LDL-C, shown to be a primary 
factor for CVD22. Additionally, the DGA recommends intake of SFA to be less than 10% 
of calories per day9. The eggs intervention had a higher intake of SFA in comparison to 
the choline bitartrate supplementation, which is primarily due to the amount of SFA in 
three eggs (4.8 g per day)10. Participants during the egg intervention were consuming 
about 35% carbohydrates daily in comparison to the choline supplement where they 
consumed 45%. According to the DGA, the recommended range for carbohydrate intake 
is 45-65% of total calories9. Recent observational studies have shown no association 
between dietary SFA and CVD risk156,157. Further research has demonstrated that 
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increased consumption of SFA in the context of a low carbohydrate diet does not 
significantly increase plasma SFA158. For this reason, higher SFA intake during the eggs 
phase was not of concern.  
 
Second, according to the DGA, the majority of fat calories should be consumed from 
monounsaturated fat (MUFA)45. MUFA is also synthesized by the liver after carbohydrate 
intake21. The majority of MUFA in Western diets is oleic acid, which is also one of the fatty 
acids in the phospholipids present in eggs71. A higher intake of dietary MUFA was 
observed during the eggs consumption in comparison to choline bitartrate 
supplementation, and no change in polyunsaturated fat (PUFA) was seen. Usually, no 
specific optimal intake for MUFA has been established, but it is based on the 
recommended intake of SFA minus PUFA21. Some studies have suggested that replacing 
5% of energy intake from SFA with MUFA resulted in a 15% lower risk for CVD36. With 
that, eggs are a great source of healthy fats that can improve diet quality and replace less 
nutritious foods when consumed with a balanced diet.  
 
The total consumption of the third macronutrient, carbohydrate, was lower during the egg 
intake period. This result was similar to what DiMarco et al.48 observed, which is not 
surprising since participants were consuming more total fat and protein, egg’s main 
macronutrients, during the eggs intervention. This reduction in carbohydrate intake can 
be explained by the consumption of eggs instead of carbohydrates, especially breakfast 
foods rich in fiber such as breads and cereals. Additionally, less legumes were consumed 
during the eggs intervention, which contain more fiber159. On the other hand, a low 
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glycemic load was observed with the consumption of eggs when compared to the choline 
bitartrate supplement, which might be related to the low glycemic index of eggs52. Low 
glycemic load foods are recommended for a healthy diet, particularly for individuals with 
diabetes160. With that, eggs are low in carbohydrates and glycemic load that can be 
incorporate into a healthy diet.  
 
Fiber and micronutrients play an important role in health, in regard to inflammation and 
biological function. During the egg consumption, fiber intake was lower which can 
compromise gut microbiota composition. Dietary fiber is a carbohydrate polymer that is 
neither digested nor absorbed, and it is fermented by the gut microbiota to produce mainly 
short chain fatty acids (SCFA)161. The importance of fiber consumption is linked to the 
influence of SCFA in gastrointestinal epithelial cell integrity, glucose homeostasis, lipid 
metabolism, appetite regulation, and immune function162. An average American 
consumes 12-18 grams/day of dietary fiber, while the DGA recommends 12 grams per 
1000 kcal9. In this study, according to the DGA, participants were supposed to consume 
about 22 grams per day of dietary fiber.  Therefore, the lower fiber intake during the eggs 
period can be explained by the consumption of eggs for breakfast instead of food rich in 
fiber, such as oatmeal, cereals, breads, and granolas, those which were commonly 
preferred during choline bitartrate supplementation when looking at the diet records.  
 
Micronutrients present in eggs such as vitamin E, found in yolk, and selenium, found in 
egg whites were higher with egg intake163. Consumption of dietary vitamin E, a natural 
antioxidant, is not met by United States adults99, which can compromise one of its 
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important function in reducing lipid peroxidation98. Additionally, selenium, also plays a role 
in the activity of antioxidant enzymes such as glutathione peroxidase106. Another nutrient, 
folate, is also present in the egg yolk (~24 µg)8, but dietary consumption of folate was 
higher in the choline bitartrate supplementation. Therefore, researchers hypothesized 
that since participants had a higher intake of fiber-rich foods during the supplement 
intervention, such as cereal and breads which are highly fortified with folic acid164, that 
may explain the higher dietary folate intake. Egg yolk also contains major carotenoids 
lutein and zeaxanthin50. One of most important functions of these carotenoids include the 
protective effect against age-related macular degeneration that has been prevalently 
increasing worldwide165. As expected, with egg consumption, these dietary carotenoids 
were higher in comparison to choline bitartrate supplement intake. Additionally, lutein has 
shown to have antioxidant activity to lower CVD associated factors such as pro-
inflammatory cytokines, aortic and plasma LDL oxidation88. Previous studies have 
demonstrated that egg consumption increases plasma carotenoids significantly50,52,76. 
Thus, proving the bioavailability of antioxidant carotenoids in eggs. Despite the low intake 
of dietary fiber, eggs have many beneficial nutrients that impact biological functions and 
promote a healthy diet.  
 
3.4.3. Anthropometrics and Plasma Biochemical Parameters  
Further investigating the effects of dietary interventions in anthropometrics and 
biochemical parameters is important, as blood was the only biological material collected 
in this study. Since these were healthy individuals, as expected, no changes in 
anthropometrics and fasting plasma glucose were observed when comparing treatments. 
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In order to assure normal kidney function, creatinine levels were measured in plasma and 
eGFR was calculated. Observing no difference in renal function was ideal since the 
metabolites of interest for Chapter 5 are cleared by the kidney166. Additionally, no changes 
in fasting plasma triglycerides was seen between treatments as these participants are 
healthy, and eggs have not previously shown to impact triacylglycerol levels48,52.  
 
On the contrary, intake of three eggs had higher impact on plasma lipids in comparison 
to choline bitartrate supplement. Total cholesterol, HDL-C and LDL-C concentrations in 
plasma were higher with the egg intake compared to choline bitartrate supplementation. 
In contrast, no change was observed in the LDL-C/HDL-C ratio, which has been shown 
to be a biomarker of CVD risk148. Importantly, the increase in HDL-C is most likely due to 
the cholesterol and phospholipids present in egg yolk that are incorporated into HDL 
particle. An increase in HDL-C has been previously shown to coincide with increased HDL 
lipid and antioxidant composition52,73,76. In previous studies, chronic consumption of 1-3 
eggs per day showed an increase in plasma HDL-C without elevating other known CVD 
risk factors in young, healthy populations48,52,76. Measurements of low-grade inflammation 
and hepatic enzymes were assessed to see the effects of both treatments in healthy, 
young adults. CRP was higher with the choline bitartrate supplementation. Additionally, 
previously studies have shown the effects of eggs in reducing inflammation53. Since these 
participants are healthy, what could have possibly caused the increase in inflammation 
was the free choline intake and increase in atherogenic metabolite TMAO peak which will 
further be discussed. Lastly, there was no significant difference in liver enzymes AST and 
ALT when comparing treatments, but an increase in AST and a trend in increasing ALT 
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was observed with choline bitartrate supplement intake. Liver enzymes in plasma are 
markers of hepatic dysfunction and injury167. Since the oxidation of trimethylamine to 
trimethylamine-N-oxide is mediated mainly by hepatic flavin monooxygenase 3 (FMO3) 
and FMO3’s role in cholesterol metabolsim140, it is possible that as a results exacerbating 
liver function cause the slight elevation in hepatic plasma enzymes. At last, Pearson’s 
correlation showed that dietary cholesterol has no association with total plasma 
cholesterol levels. Consequently, eggs can be added to a healthy dietary pattern without 
having negative effects on anthropometrics and plasma biochemical parameters.  
 
3.5. Strengths and Limitations 
The main strength of this study was the study design with a cross-over study. This way 
each subject serves as their own control. Additionally, a cross-over design has many 
strengths, including demonstrating reversibility, compensating for unsuccessful 
randomization, and improving study efficiency by not using time to recruit subjects152. 
Other strengths include the collection of dietary records and the compliance subjects 
showed which improved retention in the study. Carrying out this intervention in healthy 
individuals is also a strength, since it is not yet known the difference between two dietary 
choline sources in healthy individuals. It was ideal to understand the possible effects in 
this population before extrapolating to a population at higher risk of CVD. Finally, a great 
strength of this study was the consistency in dietary habits, which helped the researchers 
attribute the findings to the intervention treatments and no other confounding dietary 
pattern habits.  
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As all studies have limitations, one limitation of this study could be the lower intake of 
dietary fiber, which can affect the gut microbiota and have effects in other metabolic 
features159. Since the main goal here was to investigate a metabolite formed by the gut 
microbes, TMA, using dietary choline as a substrate, any dietary influence on the 
composition of the gut bacteria needed to be taken in consideration.  
 
Another limitation was the inability of assessing more nutrients in the software as well as 
intake of carnitine, TMA, and TMAO as these could also play a role on the results. On the 
contrary, food groups were assessed in a way of measuring thus compounds as they are 
present in red meat and seafood. Lastly, one more limitation was the difference in calories 
and macronutrients between treatments during the breakfast period. Even though this 
was a lifestyle intervention, it would have been interesting to match both treatments 
caloric during breakfast as this was the meal researchers advised participants to consume 
the eggs and choline bitartrate supplement.  
 
3.6. Conclusions 
Overall, this 13-week dietary intervention had the objective to evaluate the effects of 
consuming two different dietary choline sources on biomarkers for CVD risk. Even with 
the removal of upper limit for dietary cholesterol from the 2015-2020 DGA, egg 
consumption is still controversial to the majority of the population. Following intake of 
eggs, participants had higher plasma HDL-C and did not increase the LDL-C/HDL-C ratio, 
a known biomarker for heart disease risk, compared to choline bitartrate supplement. 
Additionally, dietary positive changes such as vitamin E, selenium and anti-oxidant 
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carotenoids, as well as healthy fats with lower carbohydrate intake were seen with the 
egg consumption. With that, dietary cholesterol via egg intake has no relationship with 
plasma cholesterol and impacts positively the diet of healthy young adults.  
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Chapter 4: Impact of 3 Eggs per Day Intake Compared to 
Choline Bitartrate Supplement on Apolipoproteins, HDL 
Functionality, and Cholesterol Metabolism 
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4.1. Background 
Data suggest that levels of HDL-C are inversely correlated with CVD risk107. HDL particles 
play a role in accepting excessive cellular cholesterol from extra hepatic tissues and 
delivering it to the liver in a process called reverse cholesterol transport (RCT)108. On the 
other hand, levels of LDL-C have been clearly established as a major risk factor for 
CVD108, as LDL is mainly responsible for distributing cholesterol to peripheral tissues. 
Nevertheless, apolipoproteins are emerging as better predictors for heart disease stability 
in comparison to lipoprotein cholesterol concentrations (HDL-C and LDL-C)109. 
 
The importance of HDL in RCT is to prevent the accumulation of lipids in extra hepatic 
tissues. Briefly, discoidal lipid-poor HDL associated with apolipoprotein (apo) AI will bind 
to ATP-binding cassette subfamily A member 1 transporter (ABCA1), while lipid loaded 
HDL will bind to ATP-binding cassette subfamily G member 1 transporter (ABCG1) for 
cholesterol uptake from macrophages located in the intima and/or from extra hepatic 
tissues168. Furthermore, HDL can be atheroprotective due to its composition, size and 
functional properties107. In contrast, LDL under normal physiological conditions will 
transport cholesterol to various cells and tissues, and LDL receptor (LDLR) is the major 
cell surface receptor responsible for regulating cholesterol uptake and transport169. When 
LDL is oxidized, it can be taken up by macrophages via scavenger receptors and form 
foam cells, which is the initial stage of atherosclerosis15. Thus, it is important to further 
explore HDL functionality and the modification that can occur in LDL particles.  
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HDL particles carry not only apo AI, but antioxidant enzymes, such as paraoxonase 1 
(PON1)107. Besides apo AI being the major structural protein in HDL particle, it is also 
involved in cholesterol transport and homeostasis. In addition, apo A1 has anti-
inflammatory properties due to inhibition of interleukin-1-beta (IL-1) and tumor necrosis 
factor alpha (TNF-) production in human diseases such as rheumatoid arthritis, Cohn’s 
disease and other immunoinflammatory diseases110. On the other hand, HDL has anti-
oxidant properties due to PON1 and endothelial protective effects by inducing endothelial 
nitric oxide synthase111. Studies have shown the increase in PON1 activity is associated 
with lower risk for CVD112, along with favorable changes in macrophage cholesterol 
homeostasis, consequently leading to an increase in cholesterol efflux and decrease 
biosynthesis113. Lastly, serum amyloid A (SAA) associated to HDL is an acute phase 
protein that is secreted in response to inflammation, and inversely correlated with PON1 
due to their opposing characteristics114. On the other hand, advanced oxidation protein 
products (AOPP) are mediated by oxidation from myeloperoxidase that play a role in 
atherosclerosis and inhibition of RCT mediated by HDL via SR-B1170. Therefore, there is 
an interest in understanding the role of egg intake as a dietary approach to raise HDL-C 
and HDL functionality to prevent risk for CVD.  
 
The hypothesis was that with egg intake HDL functionality would be higher while hepatic 
cholesterol biosynthesis would be lower in comparison to choline bitartrate 
supplementation. Higher functionality would be observed from higher concentration of 
apoAI and PON1 activity (arylesterase and lactonase), lower concentrations of AOPP. In 
regard to HDL metabolism, higher expression of the genes ABCA1 and ABCG1 were 
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expected with the egg intake. Secondly, egg intake would lower cholesterol biosynthesis 
pathway by lowering expression of HMGCR, LDLR, SREBP2 target genes. 
 
4.2. Materials and Methods  
4.2.1. Apolipoproteins Quantification  
Previously collected plasma was used to quantify apolipoprotein simultaneously using a 
Luminex MAGPIX Analyzer (EMD Millipore). For the purposes of this study, a Luminex 
xMAP multiplex assay kit (Invitrogen) was used to measure apolipoprotein (apo) AI, apo 
B, and apo E. The principle of this analysis is based on adding the sample to a mixture of 
color-coded beads, pre-coated with each analyte-specific capture antibodies of interest 
based on the purchased kit. In that case, the antibodies will bind to each analyte, and 
then a biotinylated detection antibody is added specific to each analyte forming an 
antibody-antigen sandwich. Then, phycoerythrin (PE) conjugated streptavidin is added, 
which will bind to the biotinylated detection antibodies. With the Luminex Magpix 
Analyzer, a magnet in the analyzer holds the magnetic beads in a monolayer, while two 
spectrally distinct light-emitting diodes (LED) illuminate the beads. One LED identifies the 
analyte that is being detected, and the second LED determines the magnitude of the PE-
derived signal. Each well is imaged with a CCD camera, and a concentration is obtained 
based on signal and standard curve of each analyte. 
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4.2.2. PON1 Activity Measurement 
Serum that was obtained from the participants at the endpoints of each intervention was 
used to measure paraoxonase 1 (PON1) activity. This enzyme has arylesterase activity 
towards phenyl acetate113. An in-house assay was developed to measure activity of 
PON1 arylesterase in half-volume 96-well plates in 270nm absorbance in a 
spectrophotometer instrument (Biotech Epoch) containing Gen5 software every 20 
seconds for 3 minutes at room temperature. Calculation was done to obtain the change 
in absorbance per minute and converted to units of enzyme activity (U) per mL using 
theoretical unique factor. 
 
4.2.3. Formation of AOPP Assay 
Advanced oxidation protein products (AOPP) were measured in serum at different end 
points of each intervention. The serum of each samples was mixed with polyethylene 
glycol (PEG) reagent (Fisher Scientific) and centrifuged at 10,000 x g for 10 min at 4oC 
to precipitate apo-B lipoproteins. Supernatant depleted of apo-B lipoproteins was 
collected, containing HDL, and added to potassium iodide plus glacial acid solution in a 
96-well plate, and incubated for 10 min at room temperature. Following, the plate was 
centrifuged at 4000 RPM for 10 min at 4oC, and supernatant was transferred to a half 
volume UV-visible 96-well plate to read absorbance at 340 nm in a spectrophotometer 
instrument (Biotech Epoch) containing Gen5 software. Concentrations of AOPP (µmol/L) 
was measured against chloramine T standard curve. 
 
 
 64 
4.2.4. Isolation of Peripheral Blood Mononuclear Cells (PBMC) 
From the blood collected at the end of each intervention, 40 mL was used for isolation of 
fresh PBMC on the same day of blood collection. First, whole blood was diluted with sterile 
phosphate buffered saline (PBS), and then layered over Ficoll Paque PREMIUM (GE 
Healthcare, Uppsala, Sweden) to form a density gradient upon centrifugation (400 x g for 
35 minutes without a brake at 20ºC). Plasma, buffy coat, Ficoll gradient and red blood 
cells are separated. The buffy coat, containing PBMCS, were collected and washed twice 
with PBS by centrifugation at 400 x g for 15 minutes at 20ºC. Following, the pellet obtained 
from the last centrifugation step was resuspended in heat-inactivated fetal bovine serum 
(FBS). Fresh PBMC was used for RNA extraction, while the remaining cells were diluted 
1:1 in a cryopreservation media (20% dimethyl sulfoxide in FBS)77. Lastly, cells were 
frozen in a CoolCell container (BioCision, LLC, Larkspur, CA) for 24 hours at -80°C, and 
then transferred to liquid nitrogen (-196°C) for long term storage.  
 
4.2.5. Gene Expression  
Using freshly isolated PBMCs, RNA was extracted with IBI Isolate reagents (IBI Scientific, 
Peosta, IA, USA) following manufacturer´s instructions. After obtaining 1 µg of RNA for 
each sample, DNase I (ThermoScientific) was used for treatment followed by reverse 
transcription using an iScript transcriptase kit (Bio-Rad, Hercules, CA, USA). Expression 
of target genes for HDL metabolism, cholesterol efflux and metabolism and apoAI 
regulation will be assessed using mRNA expression in PBMCs by quantitative real-time 
polymerase chain reaction (qRT-PCR). This analysis was done using SYBR Green with 
Bio-Rad CFX96 system (Bio-Rad, Hercules, CA, USA). Primer sequences will be 
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acquired based on the GenBank database shown in Table 6. Expression of mRNA values 
will be calculated using the threshold cycle (Ct) value. Relative expression levels of each 
target gene will be determined using the comparative 2-∆∆Ct method following 
normalization to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) mRNA 
expression171. 
 
TABLE 6 
Quantitative real-time polymerase chain reaction primer sequences 
Target Forward primer Reverse primer 
ABCA1 5′-TTTCTCAGACAACACTTGACCAAGTA-3′ 5′-GGTTTTTGTGTAATGAGAGGTCTTTTAA-3′ 
ABCG1 5′-CGGAGGGCAGCTGTGAAC-3′ 5′-GGGTCCTTCAGGAACCGAAT-3′ 
HMGCR 5’-CCCAGTTGTGCGTCTTCCA-3’ 5’-TTCGAGCCAGGCTTTCACTT-3’ 
LDLR 5’-ACTGGGTTGACTCCAAACTTCAC-3’ 5’-GGTTGCCCCCGTTGACA-3’ 
SREBP2 5’-GGGGATCCCGATGGACGACAGCGGCGGCT-3’ 5’-GGAATTCTCAGTCTGGCTCATCTTTGACCTT-3’ 
CD36 5’-GGCTGTGACCGGAACTGTG-3’ 5’-AGGTCTCCAACTGGCATTAGAA-3’ 
GAPDH 5’-TGTGGGCATCAATGGATTTGG-3 5’-ACACCATGTATTCCGGGTCAAT-3 
FMO3 5´-TGTGGGCATCAATGGATTTGG-3´ 5´-CTGGTTCTTTATAGTCCCTGCTG-3´ 
 
4.3. Results  
4.3.1. Apolipoproteins Quantification 
Apolipoproteins were measured in fasting plasma simultaneously. In comparison to 
choline bitartrate supplementation, apolipoprotein (apo) AI (p=0.002) and apo E (p=0.022) 
concentrations were higher with the egg intake (Figure 6). No differences were observed 
with apo B (Figure 6), nor apoB/apoAI ratio (0.11  0.05/0.11  0.04) when comparing 
the two treatments. 
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FIGURE 6 
Plasma concentrations of fasting apolipoproteins AI, B, and E with intake of three eggs 
versus choline bitartrate supplement for 4 weeks each. Values are presented as mean  
SD for n=29 men and women. Bar with superscripts differ at p < 0.05 as determined by 
paired Student’s t test. *p < 0.05 between interventions51 
 
4.3.2. HDL Functionality  
For measurements for HDL functionality, paraoxonase 1 (PON1) arylesterase and 
formation of advanced oxidation protein products (AOPP). There were no significant 
differences (p=0.366) in PON1 arylesterase activity in these healthy individuals when 
comparing both interventions. In addition, AOPP was also not significantly different 
(p=0.665) (Table 7).  
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TABLE 7 
High Density Lipoprotein functionality measurements for healthy young adults (n=29) 
when comparing intake of 3 eggs versus choline bitartrate supplement for 4 weeks each 
Measurements Eggs Choline p-value 
PON1 Arylesterase (U/mL) 97.22 ± 20.09 93.25 ± 17.86 0.366 
AOPP (µmol/L) 123.38 ± 25.15 125.46 ± 20.49 0.665 
 Values are presented as mean  SD. Student’s t test was used to determine statistical significance 
 
Even though no significant differences were observed with egg intake and PON1 activity, 
a correlation analysis was done. A positive correlation was observed with apoAI 
concentration (mg/L) and PON1 arylesterase activity (U/mL) (p=0.025) (Figure 7a) when 
participants were consuming eggs while no correlation (p=0.322) was observed in the 
treatment with choline bitartrate supplement (Figure 7b). On the other hand, a negative 
correlation was observed between HDL-C and CRP in this study (p=0.001). 
 
 
FIGURE 7 
Pearson’s correlation graphs between apolipoprotein AI (mg/L) and paraoxonase 1 
arylesterase activity (U/mL) for participants (n=29) consuming three eggs per day (a) or 
choline bitartrate supplement (b) for four weeks each 
a b 
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4.3.3. Gene Expression - Cholesterol Metabolism   
Finally, the changes in gene expression for cellular cholesterol biosynthesis, uptake, and 
efflux were investigated. When comparing eggs versus choline bitartrate supplement 
consumption, a lower expression of the rate-limiting enzyme HMGCR (p=0.038) and a 
key transcription factor responsible for regulating cholesterol synthesis, SREBP2 
(p=0.008), was observed. No changes were seen in efflux transporter ABCA1 (p=0.404) 
and ABCG1 (p=0.421), while a trend was detected in lowering LDLR expression 
(p=0.058) with egg intake (Figure 8). 
 
 
FIGURE 8 
Gene expression of 3-hydroxyl-3-methyl-glutaryl-coenzyme A reductase (HMGCR), low-
density lipoprotein receptor (LDLR), sterol regulatory element-binding protein 2 
(SREBP2), ATP-binding cassette subfamily A member 1 transporter (ABCA1), and ATP-
binding cassette subfamily G member 1 transporter (ABCG1) with intake of three eggs 
versus choline bitartrate supplement for 4 weeks each. Data were standardized to the 
expression of GAPDH as a reference gene using the 2(−∆∆CT) method. Values are 
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presented as mean ± SD for n=27 men and women. Bar with superscripts differ at p < 
0.05 as determined by paired Student’s t test after excluding outliers using Grubb’s test51 
 
4.4. Discussion 
4.4.1. Apolipoproteins Quantification 
Apolipoproteins are structural proteins present in lipoproteins, which contribute to the 
metabolic fate of the particle as well as its content in regards to lipid, cholesterol and 
triglycerides18. Apo AI is the major apolipoprotein associated with HDL. During this 
intervention, apo AI was elevated after the egg consumption. A major function of apo AI 
is to facilitate RCT through the interaction with cholesterol transport receptors on cellular 
membrane and accept cholesterol (from cells to lipoprotein particle)172. On the other hand, 
apo B (apo B100) is the major structural protein found in VLDL and LDL particles3. In this 
intervention, no difference was seen for plasma apo B, even though there was an increase 
in LDL-C with egg intake in comparison to choline bitartrate supplementation. This could 
be explained by an increase in the cholesterol content of LDL particles rather than the 
particle number, as there is only one apo B per LDL particle18. An possible indication of  
greater abundance of HDL particles or larger HDL can be drawn from the increase in both 
HDL-C and apo AI with egg intake, since it has been observed with previous intervention 
studies regarding egg consumption that measured particles concentration and size50,76. 
Lastly, besides measuring LDL-C/HDL-C as a biomarker for CVD, recent clinical trials are 
also reporting apoB/apoAI, and for this intervention no difference was observed with 
apolipoprotein ratio18. Another apolipoprotein that is present in the particles is apo E, 
present on VLDL and HDL. Apo E is important for decreasing plasma cholesterol and 
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clearing triglyceride-rich lipoproteins via the LDLR and LDL-receptor related protein 
(LRP)173. In this context, increase in apo E with egg intake may complement its effects on 
HDL to promote RCT to the liver for bile acid synthesis and sterol metabolism18. 
Consequently, the positive changes in apolipoprotein profile with egg intake, may explain 
the affect egg consumption has on increasing concentration of structural apolipoproteins 
that can improve HDL particle’s functionality.  
 
4.4.2. HDL Functionality  
Besides measuring serum HDL-C, the importance of HDL functionality plays a major role 
in lipid metabolism and disease risk174. Consequently, assessing HDL functionality 
enhances HDL-C findings since HDL particles exhibits anti-inflammatory, antithrombotic, 
and antioxidant effects, in addition to improving endothelial function. All of these 
properties contribute to prevention of developing atherosclerosis. Since this was a cohort 
study in healthy individuals, not much differences were expected in regard to HDL 
functionality as these individuals did not have altered HDL function from baseline. Even 
though no difference was observed in two markers of HDL function, PON1 activity and 
AOPP concentration, positive correlations were seen with treatments. Egg consumption 
shows a positive correlation between apo AI and PON1 activity, which was not seen with 
choline bitartrate supplementation. These proteins have shown to interact, and it has 
been previously shown that apo AI increases the activity of PON1175, an antioxidant 
enzyme. Additionally, dietary cholesterol has shown to increase PON1 activity in a cohort 
study evaluating food frequency questionnaires and PON1 activity in older adults, at risk 
for CVD176. Three eggs per day has shown to increase PON1 activity with increasing 
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doses of eggs (0 to 3 eggs per day for four weeks each) in healthy young adults76, while 
two eggs per day in comparison to an oatmeal breakfast did not increase PON1 activity74. 
It could be possible that the first study an additive effect was observed since there was 
no washout period between each egg dose. Another measurement of HDL functionality 
used here was AOPP concentration, as AOPP is a pro-inflammatory molecule released 
that is negative correlated with HDL-C115,177. For this intervention, no significant 
differences were observed in AOPP level, which again is due to the fact that these are 
healthy individuals. Many factors can play a role in AOPP concentrations such as age, 
gender, pregnancy, obesity, cardiovascular disorders, and fatty liver disease115. On the 
other hand, a negative correlation was observed between HDL-C and CRP levels, which 
shows the anti-inflammatory property HDL carries when there is a functional HDL174. 
Consequently, egg intake in comparison to choline bitartrate supplement has shown to 
improve HDL functionality to a certain degree in healthy young adults.   
 
4.4.3. Gene Expression - Cholesterol Metabolism   
As this was an intervention that exacerbated the recommended dietary cholesterol, 
investigating the effects on cholesterol metabolism genes of interest was essential. It is 
known that cholesterol metabolism is regulated at the cellular level and, particularly in the 
liver, and it can impact concentrations of plasma cholesterol7. A major rate limiting step 
of cholesterol biosynthesis is through the enzyme HMGCR, while the cholesterol taken 
up by the cells is regulated by LDLR interactions with circulating lipoproteins. 
Consumption of 3 eggs per day showed lower expression of HMGCR and a trend in 
lowering LDLR in comparison to choline bitartrate supplementation. This indicates that 
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with the intake of dietary cholesterol, a downregulation of HMGCR and LDLR take place 
to balance the amount of circulating cholesterol. On the other hand, SREBP genes are 
responsible for regulating over 30 genes involved in lipid homeostasis178. Specifically, 
SREBP2 is activated in response to low intracellular cholesterol levels with the function 
to promote cholesterol biosynthesis and cholesterol uptake in order to maintain cellular 
cholesterol homeostasis. With egg consumption, lower expression of SREBP2 was 
observed in comparison to choline bitartrate supplementation. Since increased levels of 
intracellular cholesterol will downregulate SREBP2 and affect the expression of HMGCR 
and LDLR179, this explains the lower expression of SREBP2 in response to the dietary 
cholesterol. As a downstream gene, SREBP2 consequently downregulated HMGCR and 
it would possible to observe a downregulation of LDLR if the study had been conducted 
for a longer period of time. Another possibility here, is that another transcription factor 
such as LXR could be regulating the expression of LDLR in this situation with higher 
intracellular cholesterol179, which would require further investigation. Surprisingly, no 
differences were observed in the ABCA1 and ABCG1 gene expressions which are to lipid 
transporters associated with HDL77. Since the major role of these transporters are 
cholesterol efflux from macrophages to HDL particles, further investigation would be 
needed as PBMCs were used in this study. Overall, with egg intake, cholesterol 
metabolism is regulated without affecting plasma levels of cholesterol, and especially no 
changes in LDL-C/HDL-C ratio. 
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4.5. Strengths and Limitations 
One great strength of this chapter was evaluating the effects of both interventions in 
healthy individuals before they become a population at higher risk for CVD, by having 
metabolic syndrome, being obese, or developing diabetes. Additionally, many biomarkers 
were assessed for basic HDL functionality; however not major changes were observed 
since these are healthy participants. Evaluating the effects of dietary cholesterol on gene 
expression changes in cholesterol metabolism was also a great strength to prove that 
there is no relationship between dietary cholesterol intake and plasma cholesterol. It has 
been shown in this study that the body is able to regulate the exogenous and endogenous 
cholesterol to maintain a healthy cholesterol plasma level.  
 
Some limitations of this intervention were the fact that measurements of lipoprotein 
particle size, diameter, and phospholipid profile of each particle was not possible to 
assess. Additionally, it would have been interesting to investigate changes in cholesterol 
efflux capacity of the HDL particles between interventions. Since TMAO has shown to 
affect cholesterol metabolism due to the role of FMO3 in the cholesterol homeostasis 
pathway129, further exploring would be interesting. Lastly, measuring other markers of 
HDL functionality such as endothelial functional proteins such as ICAM and VCAM would 
have completed the overall effects of egg consumption on increasing HDL functionality.  
 
4.6. Conclusions 
Despite the concern about egg intake regarding its dietary cholesterol content and risk 
for CVD, these data show that egg intake increases positive biomarkers that could lower 
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the risk for heart disease while others remain unchanged. Low HDL-C is an indicator of 
CVD risk, therefore raising HDL-C and HDL particle functionality has become a great 
interest to prevent heart disease complications. Overall, egg consumption suggests that 
HDL functionality is increased, which could potentially lower the risk for CVD in healthy 
young participants. The data from this intervention supports the inclusion of three eggs 
per day in a healthy dietary life pattern.  
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Chapter 5: Effects of 3 Eggs per Day Consumption Versus 
Choline Bitartrate on Plasma Choline and   
 Formation of TMAO 
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5.1. Background 
Choline is an essential nutrient in that it participates in various biological functions11. 
Some of its functions include neurotransmitter synthesis, cell-membrane signaling, lipid 
transport in the lipoproteins, and methyl-group metabolism in regards to homocysteine 
reduction11. With that, choline deficiency can result in metabolic disorders, such as fatty 
liver due to the lack of phosphatidylcholine required for formation of very-low density 
lipoprotein particles12. In fact, the average American does not meet the adequate intake 
of dietary choline, especially young adults (age 19-30)12. For this reason, egg 
consumption is of great interest due to its high content in choline, where most of the 1.3 
g of phospholipids in a large egg are phosphatidylcholine71. Additionally, about 90% of 
phospholipids are absorbed in the small intestines before reaching the gut microbiota, 
which can contribute to the elevated concentrations of choline in plasma71. 
 
In contrast to the previous observations, emerging research is targeting choline since it 
is a precursor of TMAO4. Dietary choline has been shown to be metabolized by the gut 
microbiota into TMA, which is further oxidized in the liver by FMO3 to form TMAO129. High 
concentrations of TMAO has an association with atherosclerosis progression by inducing 
the expression of scavenger receptors (CD36 and SR-A1)5, further contributing to CVD. 
There are other precursors of TMA such as L-carnitine and betaine, derived from meat 
sources and some vegetables respectively124. With that, elevated concentrations of 
plasma TMAO have shown global effects in decreasing RCT, increasing atherosclerosis 
as well as major cardiac events5. 
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For this reason, exploring the effects of egg consumption in comparison to another 
choline source will help elucidate the impact on TMAO formation and CVD risk. A small 
study in healthy individuals found an increase in postprandial plasma TMAO with an 
increasing dose of egg yolk for breakfast, which then resulted in increased concentration 
of urine TMAO145. While two studies reported no changes in fasting plasma TMAO with 
egg intake in a young healthy population at an increasing dosage of eggs48 or in 
comparison to oatmeal for breakfast74. It is important to note that there is a variation 
between individuals due to different microbial community145 as well as polymorphism in 
FMO3 gene180. Since eggs are a great source of this essential nutrient and has shown 
many other health benefits, there is the need to further understand its effect in formation 
of TMAO in comparison to another dietary choline source.  
 
The hypothesis is that egg intake would result in higher plasma choline and no change in 
plasma TMAO in comparison to baseline. While in comparison to choline bitartrate 
supplement, egg intake would result in higher plasma choline. Additionally, choline 
bitartrate supplementation was expected to increase plasma TMAO. On the other hand, 
a higher expression of scavenger receptors and FMO3 was expected with choline 
bitartrate supplementation in comparison to egg intake due to association of these genes 
with high TMAO. 
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5.2. Materials and Methods  
5.2.1. Plasma Choline and Metabolites Quantification  
Plasma free choline and its metabolites (methionine, betaine, dimethylglycine, and 
TMAO) were measured in duplicate for baseline and endpoint of each intervention by 
liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). This 
method previously established by Holm et al.181 was used with some modifications based 
on instrumentation182. Plasma was separated and aliquoted as previously mentioned, 50 
µL of each sample were mixed with 100 µL of acetonitrile (ACN) solution containing 0.1% 
formic acid and internal standards (13C3-TMAO; d13-choline). Afterwards, samples were 
vortexed vigorously for about 30 seconds each, in order to coagulate proteins. In 
sequence, samples were centrifuged for 5 min at 10,600 x g and 4oC, and then 10 µL of 
supernatant was transferred to a vial containing 120 µL of ACN and injected into the LC-
MS/MS system for analysis. The system contained an LCQ Advantage Mass 
Spectrometry system with electrospray ionization (ESI), a Surveyor High Pressure Liquid 
Chromatography system with Alltech Prevail Silica analytic column (2.1 x 150 mm, 5 µm) 
with a guard column, and a Surveyor refrigerated auto-sampler (Thermo Finnigan, San 
Jose, CA). The ESI system was operated in a positive ion mode. For this analysis, mobile 
phase was 19% ammonium formate (15 mmol) with 0.1% formic acid (v/v) and 81% ACN. 
Flow rate was set at 500 µL/min and column temperature at 25ºC. Standard curves for 
the internal standards were used for analysis. The intraassay CV was < 3.7% for each 
metabolite considering duplicate measures. In house controls were used in duplicate 
measurements and the CV was < 5.5% for each control and metabolite. 
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5.2.2. Gene expression   
As previously described, gene expression was assessed in PBMCs using target genes 
specific for TMAO metabolism (FMO3) as well as CD36 associated with atherosclerosis 
in regard to cholesterol uptake using primers on Table 2. 
 
5.3. Results  
5.3.1. Plasma Choline and Metabolites Quantification  
Since dietary choline was matched between intervention (p=0.745), plasma choline was 
analyzed to assess bioavailability in plasma following consumption from two difference 
dietary sources. In comparison to choline bitartrate supplementation, egg intake resulted 
in higher plasma choline (p=0.021) and increase from baseline (p=0.023) (Figure 9a). 
Unfortunately, there was no change in plasma TMAO in between interventions or from 
baseline (Figure 9b). Another metabolite from choline, betaine, was quantified and no 
change was observed (Figure 9c). Lastly, methionine which is part of the homocysteine 
pathway183 increased with egg consumption (p=0.005) (Figure 9d), while no change was 
observed with choline bitartrate intake (p=0.725) or between treatments (p=0.094).  
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FIGURE 9 
Plasma choline (a), trimethylamine-N-oxide (TMAO) (b), betaine (c), and methionine (d) 
concentrations before and after consuming three eggs per day or choline bitartrate 
supplement for 4 weeks each. Values are presented as means  standard deviation for 
27 young, healthy men and women. Bars with superscripts differ at p < 0.05 as 
determined by paired Student’s t test analysis after excluding outliers using Grubbs’ test. 
*significance at baseline versus end point; **significance eggs versus choline supplement 
end point; NS = not significant49 
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Intraindividual variability to egg and choline intake was observed, where some subjects 
had no impact on plasma TMAO while others increased or decreased TMAO levels in 
response to the treatments (Figure 10). 
 
 
FIGURE 10 
Intraindividual variability of plasma trimethylamine-N-oxide (TMAO) in response to egg 
and choline bitartrate intake for young, healthy adults 
 
5.3.2. Gene expression – TMAO metabolism  
When looking into gene expression for one of the main receptors, CD36 (p=0.858), 
involved in atherosclerosis progression and the key enzyme, FMO3 (p=0.392), 
responsible for forming TMAO no changes were observed within treatments in healthy 
adults (Figure 10). The other receptor, SRA, was not detectable in this population. 
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FIGURE 11 
Gene expression for cluster of differentiation 36 (CD36) and flavin monooxygenase 3 
(FMO3) using quantitative real-time polymerase chain reaction with relative quantification 
to glyceraldehyde 3-phosphate dehydrogenase (GAPDH) after consuming 3 eggs per day 
versus choline bitartrate supplement for 4 weeks each. Values are presented as means 
 standard deviation for 29 young, healthy men and women. Student’s t test was used for 
analysis after excluding outliers using Grubbs’ test49 
 
5.4. Discussion 
5.4.1. Plasma Choline and Metabolites Quantification  
This study has demonstrated that intake of ~400 mg of dietary choline, whether in the 
form of eggs or a choline supplement resulted in similar concentrations of plasma TMAO 
in a young, healthy population. However, egg intake showed an increase in plasma 
choline by 20% compared to the choline bitartrate supplement, confirming the hypothesis 
of possible increase in choline bioavailability when consumed as a component of whole 
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eggs. In contrast to what hypothesized, plasma TMAO were not different between egg 
intake and choline bitartrate supplement. However, this finding differs markedly from 
previous work which reported an increase in plasma fasting TMAO on healthy individuals 
(46 ± 5 years old) with intake ~450mg of choline per day for 8 weeks6.  
 
As choline is an essential nutrient that needs to be consumed through the diet, even 
though humans can synthesize it in small quantities11,184, the increase in plasma choline 
with egg intake is very important. Choline is involved in various biological functions12, and 
recent data from NHANES showed that 93% of adults (age ≥ 19 years) have inadequate 
intake of daily dietary choline12. Therefore, including choline rich foods in the diet is of 
great interest to prevent choline deficiency. As eggs are a good source of choline185, it is 
believed that the phosphatidylcholine form of choline in the eggs is absorbed in the ileum 
along with other lipids186, and that could explain the increase in plasma choline. These 
participants were not meeting the required intake of dietary choline before the intervention 
since their baseline dietary choline intake was 293.41  97.0 mg/day (data not shown), 
and the adequate intake (AI) for dietary choline is 550 mg/day  for males and 425 mg/day 
females12. With the intervention they were consuming an additional ~400 mg/day of 
dietary choline that was coming from either the eggs or the supplement, and therefore 
reaching the daily AI.   
 
A possible explanation for the differences in plasma TMAO with the other study 
mentioned above could be the due to the role of the methyl donor pathway in this study183. 
Individuals consuming eggs had higher plasma choline, betaine, dimethylglycine (DMG) 
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and methionine while no changes in plasma TMAO (Figure 12). On the other hand, when 
individuals were consuming choline bitartrate supplement no change in plasma choline 
was observed, while a higher plasma betaine and DMG was seen, and no change in 
methionine and plasma TMAO. Considering the methyl donor pathway, and the fact that 
these participants were deficient in dietary choline according to the study in 201612, all 
the methyl donor pathway precursors were being used due to this “deficiency” (Figure 
12). For the egg consumption, since choline is more bioavailable that was the source of 
the methyl donor. While in the choline bitartrate supplement period, an increase in dietary 
folate and betaine was observed which could contribute to the methyl donor pathway, but 
it was still probably not enough to see similar change in methionine as in the eggs. 
Additionally, these individuals has normal kidney function, which can be a factor in 
accumulation of TMAO and increase in plasma TMAO187. Notably, the interindividual 
variation in plasma TMAO is very large6,182. In this current study, participants are 
characterized as having low fasting plasma TMAO concentrations in comparison to 
individuals with CVD phenotypes4. Clearly, in this intervention, egg intake increased 
plasma choline and did not alter the concentrations of TMAO when compared to baseline 
values or choline supplement. 
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FIGURE 12 
The role of choline from egg consumption (white) and choline bitartrate (black) 
supplementation in homocysteine pathway and TMAO formation when comparing 
changes from baseline to end of each intervention (adapted from Olthof et al. 2005)183 
 
Another reason for not observing change in fasting plasma TMAO is the fact that these 
are healthy young adults. Elevated plasma TMAO has been correlated to CVD risk in 
population prone to a cardiovascular events, such as coronary artery disease and 
myocardial infarction4. Furthermore, TMAO can be converted back to TMA by TMAO 
reductase188, and TMA can be cleared by the kidneys137, particularly in this study, the 
participants had normal creatinine levels throughout the intervention which is a marker 
for normal renal function. Nevertheless, TMAO/TMA can be cleared by the kidney and 
not accumulate or circulate throughout the body187. Additionally, the interindividual 
composition of the gut microbiota as well as FMO3 activity can be a contributor factor to 
of choline supplementation on plasma homocysteine concentra-
tions in healthy subjects are unknown. Therefore, we investi-
gated the effect of supplementation with choline (as phosphati-
dylcholine) on fasting and postmethionine-loading plasma
concentrations of homocysteine in healthy men.
SUBJECTS AND METHODS
Subjects
Subjects were recruited from the pool of volunteers registered
at the Netherlands Organisation for Applied Scientific Research
(TNO) Quality of Life (Zeist, Netherlands) and by advertise-
ments in local newspapers. Eligible volunteers were healthy as
assessed by physical examination, a general health and lifestyle
questionnaire, blood pressure measurement, routine clinical lab-
oratory tests, and blood analyses of tHcy and B vitamins. Plasma
tHcy concentrations were 26 mol/L. Volunteers had no his-
tory of CVD and had not used vitamin B supplements, lecithin,
or supplements containing choline, choline derivatives, or be-
taine 1 time/wk during the month preceding screening.
Of 48 eligible men, 26 men aged 50–71 y with the highest
plasma tHcy concentrations (range: 11.0–23.1 mol/L) were
included in this study. Subject characteristics are shown inTable
1. All subjects completed the study.
Written informed consent was obtained from all subjects. The
study was conducted according to Good Clinical Practice guide-
lines at TNOQuality of Life. The localmedical ethics committee
approved the protocol.
Study design
In this double-blind, placebo-controlled, crossover study, the
subjects were randomly assigned to 1 of 2 treatment orders.
Randomization was stratified by plasma tHcy concentrations at
screening and by smoking habits. Thirteen subjects began phos-
phatidylcholine treatment, and the other 13 began placebo treat-
ment, both for 2 wk. After a 2-wk washout period, the treatments
were reversed. Treatments consisted of ingestion of 34.0 g of a
FIGURE 1. The role of choline in homocysteine metabolism. Box: structure of phosphatidylcholine
TABLE 1
Subject characteristics at screening1
Value
Age (y) 61 6
BMI (kg/m2) 27.7 2.2
tHcy ( mol/L) 14.7 3.4
Vit min B-6 (nmol/L) 64 44
Vitamin B-12 (pmol/L) 236 61
Folate (nmol/L) 11.7 3.9
ALP (U/L) 73 16
ALT (U/L) 21 8
AST (U/L) 21 6
-GT (U/L) 25.7 11.0
Creatinine ( mol/L) 88 11
1 All values are x SD; n 26. All measurements in blood were taken
after an overnight fast. tHcy, total homocysteine; ALP, alkaline phosphatase;
ALT, alanine aminotransferase; AST, aspartate aminotransferase; GT, glu-
tamyltransferase.
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Downloaded from https://academic.oup.com/ajcn/article-abstract/82/1/111/4863306
by University of Connecticut Health Center - L.M. Stowe Library - Collection Management user
on 22 August 2018
Eggs
Choline
Diet - Choline
TMA TMAO
Gut microbiota Fmo3
URINE
Normal Kidney
function 
 86 
TMAO plasma levels48. As observed in this study (Figure 10), according to previously 
shown145, there is also an intraindividual variability in response to egg consumption. Only 
14% of choline consumed as phosphatidylcholine, as it is in eggs, is metabolized to 
TMAO145. Overall, this study confirms that when the same amount of dietary choline is 
consumed, it is more bioavailable in eggs compared to choline bitartrate supplementation.  
 
5.4.2. Gene expression – TMAO metabolism 
Plasma TMAO has been shown to increase expression of scavenger receptors 
responsible for uptake of modified LDL, therefore the reasoning for measuring gene 
expression of one of these receptors. All though TMAO was measured in the fasted state, 
it was expected to observe an increase in expression of these receptors145. CD36 did not 
increase as expected with the choline bitartrate supplement intake in comparison to egg 
consumption. A possible explanation to this phenomenon is that since there is no increase 
in FMO3 expression, which is the main enzyme responsible for the conversion of TMA to 
TMAO129, no change in plasma TMAO is observed when comparing egg intake and 
choline bitartrate supplement. In addition, these are healthy adults as documented by 
their baseline biochemical parameters. Therefore, if TMAO is not elevated in plasma 
consequently expression of CD36 will not be increased in order to promote the uptake of 
modified LDL and further progress into plaque formation. 
 
5.5. Strengths and Limitations 
Since this is the first dietary intervention comparing egg intake versus a dietary 
supplement, the ideal scenario was to first investigate the effects in healthy individuals. 
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In that case, the results for thus populations is known before investigating the effects of 
such intervention in other participants at higher risk for CVD. Another strength of this 
study was controlling renal function throughout the intervention as kidney clearance can 
be a confounding factor in plasma TMAO analysis and data interpretation.  
 
One limitation from our study could be the length on the intervention in order to reach that 
threshold, if there is one, for increases in plasma TMAO between these two treatments. 
Since there is a high interindividual variability of plasma TMAO145, this could have also 
played a role in the analysis. Even though a good number of subjects was used for this 
intervention, when separating participants by high and low TMAO producers and number 
was small to detect significance. Another confounding factor is the variance in gut 
microbiota among individuals189 and in this study no fecal samples were collected for 
characterization of the microbiota species. Collection of fecal samples would allow 
identification of gut bacteria responsible for the conversion of choline to TMA in the 
colon130. Another limitation is collecting fasting plasma, which could mean the peak of 
plasma TMAO was missed for this intervention, but goal was to evaluate the long effect 
of accumulating plasma TMAO as it has been seen in CVD risk population. Lastly, a great 
limitation is using PBMCs for gene expression as FMO3 is highly expressed in the liver129. 
Therefore, a more representative sample would help understand the metabolism and role 
of FMO3 in regard to different sources of dietary choline.  
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5.6. Conclusions 
Overall, despite what has been previously shown as egg intake increasing plasma TMAO, 
these data show that it was not true. Eggs have dietary choline, but it does not increase 
circulating plasma TMAO in healthy individuals. In fact, it is a great source of dietary 
choline and many other nutrients. With that, it is safe to say that eggs may be incorporated 
in the diet to meet the adequate intake of choline, an essential nutrient. 
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Chapter 6: Conclusion and Future Directions 
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For decades, egg consumption has been a controversial food because of its high 
cholesterol, saturated fat and recently, choline content. Therefore, much research has 
been done to explore the effects of egg intake in risk for CVD, especially populations of 
concern such as metabolic syndrome, diabetic and chronic renal disease people. Now 
with the emerging interest in the plasma TMAO as a predictor and factor in CVD risk4, 
and eggs having high dietary choline, a known precursor for TMAO formation, more 
research is needed to investigate the effects of this rich and affordable food. Since not 
many studies have compared different sources of dietary choline and formation of TMAO, 
this was a novel trial, and it sets up the stage to many other studies to come. 
 
The results from this study confirmed the hypothesis that egg intake did not increase risk 
for CVD in healthy young adults. Importantly, biomarkers of CVD risk were improved with 
egg intake such as HDL-C and HDL functionality. Additionally, intake of three eggs per 
day resulted in higher intake of nutrients present in eggs, including vitamin E, selenium, 
lutein and zeaxanthin in comparison to choline bitartrate supplement consumption. 
Plasma choline concentrations were increased with egg intake without affecting plasma 
TMAO, which contributes to the importance that choline has in biological functions. Egg 
consumption also regulated cholesterol biosynthesis pathway in order to maintain a 
balance between exogenous and endogenous cholesterol without raising LDL-C/HDL-C 
ratio, an important biomarker of CVD. Unfortunately, the hypothesis that choline bitartrate 
supplement intake would increase plasma TMAO was not supported, and further research 
is needed in the field.  
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Considering the results here obtained, as well as the limitations mentioned throughout 
the chapters, the next step would be evaluating the effects of these treatments in a 
population at risk. Investigating the effects of egg consumption in comparison to choline 
bitartrate in metabolic syndrome and diabetics would be ideal. Since previous data with 
egg intake in individuals with metabolic syndrome and diabetes have not raised risk for 
CVD53,75, comparing to choline bitartrate supplementation would give great insight to the 
formation of TMAO regarding both treatments. Another future direction would also be 
collecting fecal and urine samples to evaluate the kinetics of TMAO formation and 
clearance and relate that to dietary intake. It would be really interesting to see the effects 
of postprandial intake of both treatments and TMAO formation to further understand the 
metabolism of choline from dietary sources. Lastly, since FMO3 activity and phenotype 
can be factored by gender and polymorphism, it would be interesting to see phenotype of 
these individuals at higher risk for CVD and how TMAO formation would play a role in 
increasing the risk.  
  
 92 
References 
1. Nabel, E. G. Cardiovascular disease. N. Engl. J. Med. 60–72 (2003). 
2. Torres, N., Guevara-Cruz, M., Velázquez-Villegas, L. A. & Tovar, A. R. Nutrition 
and Atherosclerosis. Arch. Med. Res. 46, 408–426 (2015). 
3. Allaire, J., Vors, C., Couture, P. & Lamarche, B. LDL particle number and size and 
cardiovascular risk. Curr. Opin. Lipidol. 28, 261–266 (2017). 
4. Wang, Z. et al. Gut flora metabolism of phosphatidylcholine promotes 
cardiovascular disease. Nature 472, 57–63 (2011). 
5. Tang, W. H. W. & Hazen, S. L. The contributory role of gut microbiota in 
cardiovascular disease. J. Clin. Invest. 124, (2014). 
6. Zhu, W., Wang, Z., Tang, W. H. W. & Hazen, S. L. Gut Microbe-Generated 
Trimethylamine-N-Oxide From Dietary Choline Is Prothrombotic in Subjects. 
Circulation 135, 1671–1673 (2017). 
7. Barona, J. & Fernandez, M. L. Dietary Cholesterol Affects Plasma Lipid Levels, 
the Intravascular Processing of Lipoproteins and Reverse Cholesterol Transport 
without Increasing the Risk for Heart Disease. 1015–1025 (2012). 
doi:10.3390/nu4081015 
8. Andersen, C. J. Bioactive Egg Components and Inflammation. Nutrients 7889–
7913 (2015). doi:10.3390/nu7095372 
9. Agriculture, U. S. D. of H. and H. S. and U. S. D. of. 2015 – 2020 Dietary 
Guidelines for Americans. 2015 – 2020 Diet. Guidel. Am. (8th Ed. 18 (2015). 
doi:10.1097/NT.0b013e31826c50af 
10. USDA. Food Composition Databases Show Foods -- Egg, whole, raw, fresh. 
 93 
Available at: https://ndb.nal.usda.gov/ndb/foods/show/112. (Accessed: 28th 
November 2017) 
11. Zeisel, S. H. & Da Costa, K. A. Choline: An Essential Nutrient for Public Health. 
Nutr. Rev. 67, 615–623 (2009). 
12. Wallace, T. C. & III, V. L. F. Assessment of Total Choline Intakes in the United 
States. J. Am. Coll. Nutr. 35, 108–112 (2016). 
13. Soliman, G. Dietary Cholesterol and the Lack of Evidence in Cardiovascular 
Disease. Nutrients 10, 780 (2018). 
14. What is Cardiovascular Disease? American Heart Association (2017). Available 
at: http://www.heart.org/en/health-topics/consumer-healthcare/what-is-
cardiovascular-disease.  
15. Moore, K., Sheedy, F. & Fished, E. Macrophages in atherosclerosis : a dynamic 
balance. Nat Rev Immunol 13, 709–721 (2015). 
16. Ghosh, S., Zhao, B., Bie, J. & Song, J. Macrophage cholesteryl ester mobilization 
and atherosclerosis. Vascul. Pharmacol. 52, 1–10 (2010). 
17. Randolph, G. J. & Miller, N. E. Lymphatic transport of high-density lipoproteins 
and chylomicrons. J. Clin. Invest. 124, 929–935 (2014). 
18. Marcovina, S. & Packard, C. J. Measurement and meaning of apolipoprotein AI 
and apolipoprotein B plasma levels. J. Intern. Med. 259, 437–446 (2006). 
19. Moore, K. J. & Freeman, M. W. Scavenger receptors in atherosclerosis: Beyond 
lipid uptake. Arterioscler. Thromb. Vasc. Biol. 26, 1702–1711 (2006). 
20. Wang, S., Peng, D. Q. & Yi, Y. The unsolved mystery of apoA-I recycling in 
adipocyte. Lipids Health Dis. 15, 1–8 (2016). 
 94 
21. Liu, A. G. et al. A healthy approach to dietary fats: understanding the science and 
taking action to reduce consumer confusion. Nutr. J. 16, 53 (2017). 
22. Briggs, M. A., Petersen, K. S. & Kris-Etherton, P. M. Saturated Fatty Acids and 
Cardiovascular Disease: Replacements for Saturated Fat to Reduce 
Cardiovascular Risk. Healthcare 5, (2017). 
23. Mensink, R. P. Effects of saturated fatty acids on serum lipids and lipoproteins: a 
systematic review and regression analysis. (World Health Organization, 2016). 
24. Rehm, C. D., Peñalvo, J. L., Afshin, A. & Mozaffarian, D. Dietary Intake Among 
US Adults, 1999-2012. Jama 315, 2542 (2016). 
25. Jakobsen, M. U. et al. Major types of dietary fat and risk of coronary heart 
disease : a pooled analysis of 11 cohort studies 1 – 3. Am. J. Clin. Nutr. 89, 1425–
1433 (2009). 
26. Wang, D. . et al. Specific dietary fats in relation to total and cause-specific 
mortality. JAMA Int. Med. 133, 1134–1145 (2016). 
27. St-Onge, M.-P. & Jones, P. J. H. Physiological Effects of Medium- Chain 
Triglycerides: Potential Agents in the Prevention of Obesity. Clin. Trials 132, 329–
332 (2002). 
28. Sampath, H. & Ntambi, J. M. The fate and intermediary metabolism of stearic 
acid. Lipids 40, 1187–1191 (2005). 
29. Agriculture, U. S. D. of A. Nutrient List: Fatty acids, total monounsaturated(g). 
USDA Food Composition Databases (2018). Available at: 
https://ndb.nal.usda.gov/ndb/nutrients/report?nutrient1=645&nutrient2=&nutrient3
=&fg=&max=25&subset=0&offset=0&sort=c&totCount=7786&measureby=g.  
 95 
30. Schwingshackl, L., Strasser, B. & Hoffmann, G. Effects of monounsaturated fatty 
acids on cardiovascular risk factors: A systematic review and meta-analysis. Ann. 
Nutr. Metab. 59, 176–186 (2011). 
31. Gillingham, L. G., Harris-Janz, S. & Jones, P. J. H. Dietary monounsaturated fatty 
acids are protective against metabolic syndrome and cardiovascular disease risk 
factors. Lipids 46, 209–228 (2011). 
32. Liu, X. et al. Fat Mass in Individuals with Central Obesity. 24, 2261–2268 (2017). 
33. Hammad, S., Pu, S. & Jones, P. J. Current Evidence Supporting the Link 
Between Dietary Fatty Acids and Cardiovascular Disease. Lipids 51, 507–517 
(2016). 
34. Kien, C. L. et al. Dietary intake of palmitate and oleate has broad impact on 
systemic and tissue lipid profiles in humans. Am. J. Clin. Nutr. 99, 436–445 
(2014). 
35. Skeaff, C. M. & Miller, J. Dietary fat and coronary heart disease: Summary of 
evidence from prospective cohort and randomised controlled trials. Ann. Nutr. 
Metab. 55, 173–201 (2009). 
36. Li, Y. et al. Saturated Fat as Compared With Unsaturated Fats and Sources of 
Carbohydrates in Relation to Risk of Coronary Heart Disease: A Prospective 
Cohort Study. J Am Coll Cardiol 66, 1538–1548 (2016). 
37. Mozaffarian, D., Micha, R. & Wallace, S. Effects on coronary heart disease of 
increasing polyunsaturated fat in place of saturated fat: A systematic review and 
meta-analysis of randomized controlled trials. PLoS Med. 7, (2010). 
38. Wu, J. H. et al. Circulating Omega-6 Polyunsaturated Fatty Acids and Total and 
 96 
Cause-Specific Mortality: The Cardiovascular Health Study. Circulation 130, 
1245–1253 (2014). 
39. Wrona, A., Balbus, J., Hrydziuszko, O. & Kubica, K. Two-compartment model as a 
teaching tool for cholesterol homeostasis. Adv. Physiol. Educ. 39, 372–377 
(2015). 
40. Baggaley, A. An Ilustrated Guide to Every Part of the Human Body and How It 
Works. (Dorling Kindersley, 2001). 
41. Goedeke, L. & Fernández-Hernando, C. Regulation of cholesterol homeostasis. 
Cell. Mol. Life Sci. 69, 915–930 (2012). 
42. Agriculture, U. D. of. Per capita consumption of eggs in the United States from 
2000 to 2018. Statista (2018). Available at: 
https://www.statista.com/statistics/183678/per-capita-consumption-of-eggs-in-the-
us-since-2000/. (Accessed: 4th October 2018) 
43. McNamara, D. J. Dietary cholesterol and atherosclerosis. Biochim. Biophys. Acta 
- Mol. Cell Biol. Lipids 1529, 310–320 (2000). 
44. Xu, Z., McClure, S. & Appel, L. Dietary Cholesterol Intake and Sources among 
U.S Adults: Results from National Health and Nutrition Examination Surveys 
(NHANES), 2001–2014. Nutrients 10, 771 (2018). 
45. Miranda, J. M. et al. Egg and egg-derived foods: Effects on human health and use 
as functional foods. Nutrients 7, 706–729 (2015). 
46. USDA. National nutrient database for standard reference 1 release —egg, whole, 
raw, fresh. (2018). 
47. Song, W. O. & Kerver, J. M. Nutritional Contribution of Eggs to American Diets. J. 
 97 
Am. Coll. Nutr. 19, 556S–562S (2000). 
48. DiMarco, D. M. et al. Intake of up to 3 Eggs/Day Increases HDL Cholesterol and 
Plasma Choline While Plasma Trimethylamine-N-oxide is Unchanged in a Healthy 
Population. Lipids 52, 255–263 (2017). 
49. Lemos, B. S. et al. Effects of Egg Consumption and Choline Supplementation on 
Plasma Choline and Trimethylamine-N-Oxide in a Young Population. J. Am. Coll. 
Nutr. 0, 1–8 (2018). 
50. Blesso, C. N., Andersen, C. J., Bolling, B. W. & Fernandez, M. L. Egg intake 
improves carotenoid status by increasing plasma HDL cholesterol in adults with 
metabolic syndrome. Food Funct. 4, 213–221 (2013). 
51. Lemos, B. S., Medina-Vera, I., Blesso, C. N. & Fernandez, M. Intake of 3 Eggs 
per Day When Compared to a Choline Bitartrate Supplement, Downregulates 
Cholesterol Synthesis without Changing the LDL/HDL Ratio. Nutrients 10, 258 
(2018). 
52. Missimer, A. et al. Consuming two eggs per day, as compared to an oatmeal 
breakfast, increases plasma ghrelin while maintaining the LDL/HDL ratio. 
Nutrients 9, (2017). 
53. Ballesteros, M. N. et al. One egg per day improves inflammation when compared 
to an oatmeal-based breakfast without increasing other cardiometabolic risk 
factors in diabetic patients. Nutrients 7, 3449–3463 (2015). 
54. National Research Council (US) Subcommittee on the Tenth Edition of the 
Recommended Dietary Allowances. Recommended Dietary Allowances. (National 
Academies Press (US), 1989). 
 98 
55. Eilat-Adar, S., Sinai, T., Yosefy, C. & Henkin, Y. Nutritional recommendations for 
cardiovascular disease prevention. Nutrients 5, (2013). 
56. Holt, L. e et al. A Satiety Index of Common Foods. European Journal of Clinical 
Nutrition 49, 675–690 (1995). 
57. Ratliff, J. et al. Consuming eggs for breakfast influences plasma glucose and 
ghrelin, while reducing energy intake during the next 24 hours in adult men. Nutr. 
Res. 30, 96–103 (2010). 
58. Dit El Khoury, D. T., Obeid, O., Azar, S. T. & Hwalla, N. Variations in postprandial 
ghrelin status following ingestion of high-carbohydrate, high-fat, and high-protein 
meals in males. Ann. Nutr. Metab. 50, 260–269 (2006). 
59. Blom, W. A. et al. Effect of a high-fat meal on the postprandial ghrelin response. 
Am. J. Clin. Nutr. 84, 664–665 (2006). 
60. Lewis, J. C., Snell, N. S., Hirschmann, D. J. & Fraenkel-Conrat, H. Amino Acid 
Composition of Egg Proteins. J. Biol. Chem 186, 23–25 (1950). 
61. Hida, A. et al. Effects of egg white protein supplementation on muscle strength 
and serum free amino acid concentrations. Nutrients 4, 1504–1517 (2012). 
62. Glynn, E. L. et al. Excess Leucine Intake Enhances Muscle Anabolic Signaling but 
Not Net Protein Anabolism in Young Men and Women. J. Nutr. 140, 1970–1976 
(2010). 
63. Jahan-Mihan, A., Luhovyy, B. L., Khoury, D. El & Harvey Anderson, G. Dietary 
proteins as determinants of metabolic and physiologic functions of the 
gastrointestinal tract. Nutrients 3, 574–603 (2011). 
64. Kovacs-Nolan, J., Phillips, M. & Mine, Y. Advances in the value of eggs and egg 
 99 
components for human health. J. Agric. Food Chem. 53, 8421–8431 (2005). 
65. Evenepoel, P. et al. Digestibility of cooked and raw egg protein in humans as 
assessed by stable isotope techniques. J. Nutr. 128, 1716–22 (1998). 
66. Lee, M. et al. Hen Egg Lysozyme Attenuates Inflammation and Modulates Local 
Gene Expression in a Porcine Model of Dextran Sodium Sulfate (DSS) -Induced 
Colitis. J. Agric. Food Chem. 57, 2233–2240 (2009). 
67. Kobayashi, Y. et al. Oral administration of hen egg white ovotransferrin attenuates 
the development of colitis induced by dextran sodium sulfate in mice. J. Agric. 
Food Chem. 63, 1532–1539 (2015). 
68. Sattar Khan, M. A. et al. Bactericidal action of egg yolk phosvitin against 
Escherichia coli under thermal stress. J. Agric. Food Chem. 48, 1503–1506 
(2000). 
69. Fujita, H., Sasaki, R. & Yoshikawa, M. Potentiation of the antihypertensive activity 
of orally administered ovokinin, a vasorelaxing peptide derived from ovalbumin, by 
emulsification in egg phosphatidylcholine. Biosci. Biotech. Biochem. 59, 2344–
2345 (1995). 
70. Cohn, J. S., Kamili, A., Wat, E., Chung, R. W. S. & Tandy, S. Dietary 
phospholipids and intestinal cholesterol absorption. Nutrients 2, 116–127 (2010). 
71. Blesso, C. N. Egg phospholipids and cardiovascular health. Nutrients 7, 2731–
2747 (2015). 
72. Zierenberg, O. & Grundy, S. M. Intestinal absorption of 
polyenephosphatidylcholine in man. Jouranl Lipid Res. 23, 1136–1142 (1982). 
73. Andersen, C. et al. Egg Consumption Modulates HDL Lipid Composition and 
 100 
Increases the Cholesterol-Accepting Capacity of Serum in Metabolic Syndrome. 
Lipids 29, 997–1003 (2013). 
74. Missimer, A. et al. Compared to an Oatmeal Breakfast, Two Eggs/Day Increased 
Plasma Carotenoids and Choline without Increasing Trimethyl Amine N -Oxide 
Concentrations. J. Am. Coll. Nutr. 37, 140–148 (2018). 
75. Blesso, C. N., Andersen, C. J., Barona, J., Volek, J. S. & Fernandez, M. L. Whole 
egg consumption improves lipoprotein profiles and insulin sensitivity to a greater 
extent than yolk-free egg substitute in individuals with metabolic syndrome. 
Metabolism. 62, 400–410 (2013). 
76. DiMarco, D. M., Norris, G. H., Millar, C. L., Blesso, C. N. & Fernandez, M. L. 
Intake of up to 3 Eggs per Day Is Associated with Changes in HDL Function and 
Increased Plasma Antioxidants in Healthy, Young Adults. J. Nutr. jn241877 
(2017). doi:10.3945/jn.116.241877 
77. Andersen, C. J., Lee, J. Y., Blesso, C. N., Carr, T. P. & Fernandez, M. L. Egg 
intake during carbohydrate restriction alters peripheral blood mononuclear cell 
inflammation and cholesterol homeostasis in metabolic syndrome. Nutrients 6, 
2650–2667 (2014). 
78. Tokés, T. et al. Protective effects of a phosphatidylcholine-enriched diet in 
lipopolysaccharide-induced experimental neuroinflammation in the rat. Shock 36, 
458–465 (2011). 
79. Ehehalt, R. et al. Phosphatidylcholine and lysophosphatidylcholine in intestinal 
mucus of ulcerative colitis patients. A quantitative approach by nanoelectrospray-
tandem mass spectrometry. Scand. J. Gastroenterol. 39, 737–742 (2004). 
 101 
80. Erös, G., Ibrahim, S., Siebert, N., Boros, M. & Vollmar, B. Oral 
phosphatidylcholine pretreatment alleviates the signs of experimental rheumatoid 
arthritis. Arthritis Res. Ther. 11, 1–10 (2009). 
81. Miettinen, T. A. & Gylling, H. Cholesterol absorption efficiency and sterol 
metabolism in obesity. Atherosclerosis 153, 241–248 (2000). 
82. César, T. B., Oliveira, M. R. M., Mesquita, C. H. & Maranhão, R. C. High 
cholesterol intake modifies chylomicron metabolism in normolipidemic young 
men. J. Nutr. 136, 971–6 (2006). 
83. Karadas, F., Pappas, A. C., Surai, P. F. & Speake, B. K. Embryonic development 
within carotenoid-enriched eggs influences the post-hatch carotenoid status of the 
chicken. Comp. Biochem. Physiol. - B Biochem. Mol. Biol. 141, 244–251 (2005). 
84. Nimalaratne, C., Savard, P., Gauthier, S. F., Schieber, A. & Wu, J. 
Bioaccessibility and Digestive Stability of Carotenoids in Cooked Eggs Studied 
Using a Dynamic in Vitro Gastrointestinal Model. J. Agric. Food Chem. 63, 2956–
2962 (2015). 
85. Vishwanathan, R., Goodrow-Kotyla, E. F., Wooten, B. R., Wilson, T. A. & Nicolosi, 
R. J. Consumption of 2 and 4 egg yolks/d for 5 wk increases macular pigment 
concentrations in older adults with low macular pigment taking cholesterol-
lowering statins. Am. J. Clin. Nutr. 90, 1272–1279 (2009). 
86. Wenzel, A. J. et al. A 12-wk egg intervention increases serum zeaxanthin and 
macular pigment optical density in women. J. Nutr. 136, 2568–73 (2006). 
87. Krinsky, N. I., Landrum, J. T. & Bone, R. A. BIOLOGIC MECHANISMS OF THE 
PROTECTIVE ROLE OF LUTEIN AND ZEAXANTHIN IN THE EYE. Annu. Rev. 
 102 
Nutr. 23, 171–201 (2003). 
88. Kim, J. E. et al. A Lutein-Enriched Diet Prevents Cholesterol Accumulation and 
Decreases Oxidized LDL and Inflammatory Cytokines in the Aorta of Guinea Pigs. 
J. Nutr. 141, 1458–1463 (2011). 
89. Serpeloni, J. M. et al. Dietary carotenoid lutein protects against DNA damage and 
alterations of the redox status induced by cisplatin in human derived HepG2 cells. 
Toxicol. Vitr. 26, 288–294 (2012). 
90. Fernández-Robredo, P., Rodríguez, J. A., Sádaba, L. M., Recalde, S. & García-
Layana, A. Egg yolk improves lipid profile, lipid peroxidation and retinal 
abnormalities in a murine model of genetic hypercholesterolemia. J. Nutr. 
Biochem. 19, 40–48 (2008). 
91. Alves-Rodrigues, A. & Shao, A. The science behind lutein. Toxicol. Lett. 150, 57–
83 (2004). 
92. Ma, L. & Lin, X. M. Effects of lutein and zeaxanthin on aspects of eye health. J. 
Sci. Food Agric. 90, 2–12 (2010). 
93. Stahl, W. & Sies, H. Antioxidant activity of carotenoids. Mol. Aspects Med. 24, 
345–351 (2003). 
94. Goodrow, E. F. et al. Consumption of one egg per day increases serum lutein and 
zeaxanthin concentrations in older adults without altering serum lipid and 
lipoprotein cholesterol concentrations. J. Nutr. 136, 2519–24 (2006). 
95. Natoli, S., Markovic, T., Lim, D., Noakes, M. & Kostner, K. Unscrambling the 
research: Eggs, serum cholesterol and coronary heart disease. Nutr. Diet. 64, 
105–111 (2007). 
 103 
96. Nimalaratne, C. & Wu, J. Hen egg as an antioxidant food commodity: A review. 
Nutrients 7, 8274–8293 (2015). 
97. Gulçin, I. Antioxidant capacity of food constituents: an overview. Arch Toxicol 
345–391 (2012). doi:10.1007/s00204-011-0774-2 
98. Kim, J. E., Ferruzzi, M. G. & Campbell, W. W. Egg Consumption Increases 
Vitamin E Absorption from Co-Consumed Raw Mixed Vegetables in Healthy 
Young Men. J. Nutr. 146, 2199–2205 (2016). 
99. USDA. Scientific Report of the 2015 Dietary Guidelines Advisory Committee. 
(2015). 
100. Rimm, E. B. et al. Vitamin E Consumption and the Risk of Coronary Heart 
Disease in Men. N Engl J Med 328, 1450–1456 (1993). 
101. Stampfer, M. J. & Willett, W. C. Vitamin E Consumption and the Risk of Coronary 
Heart Disease in Women. N Engl J Med 328, 1444–1449 (1993). 
102. Yetley, E. A. Assessing the vitamin D status of the US population. Am. J. Clin. 
Nutr. 88, 558–564 (2008). 
103. Kulie, T., Groff, A., Redmer, J., Hounshell, J. & Schrager, S. Vitamin D: An 
Evidence-Based Review. J. Am. Board Fam. Med. 22, 698–706 (2009). 
104. Nakamura, S., Kato, A. & Kobayashi, K. Enhanced Antioxidative Effect of 
Ovalbumin Due to Covalent Binding of Polysaccharides. J. Agric. Food Chem. 40, 
2033–2037 (1992). 
105. Davalos, A., Miguel, M., Bartolome, B. & Lopez-Fandino, R. Antioxidant Activity of 
Peptides Derived from Egg White Proteins by Enzymatic Hydrolysis. J. Food Prot. 
67, 1939–1944 (2004). 
 104 
106. Burk, R. F. & Hill, K. E. Regulation of Selenium Metabolism and Transport. Annu. 
Rev. Nutr. 35, 109–134 (2015). 
107. Andersen, C. J. & Fernandez, M. L. Dietary approaches to improving 
atheroprotective HDL functions. Food Funct. 4, 1304–1313 (2013). 
108. Hafiane, A. & Genest, J. HDL, atherosclerosis, and emerging therapies. 
Cholesterol 2013, (2013). 
109. Rasouli, M., Kiasari, A. M. & Mokhberi, V. The ratio of apoB/apoAI, apoB and 
lipoprotein (a) are the best predictors of stable coronary artery disease. 44, 1015–
1021 (2006). 
110. Mangaraj, M., Nanda, R. & Panda, S. Apolipoprotein A-I: A Molecule of Diverse 
Function. Indian J. Clin. Biochem. 31, 253–259 (2016). 
111. Chyu, K. Y. & Shah, P. K. HDL/ApoA-1 infusion and ApoA-1 gene therapy in 
atherosclerosis. Front. Pharmacol. 6, 1–9 (2015). 
112. Femlak, M., Gluba-Brzozka, A., Cialkowska-Rysz, A. & Rysz, J. The role and 
function of HDL in patients with diabetes mellitus and the related cardiovascular 
risk. Lipids Health Dis. 16, 207 (2017). 
113. Farrell, N., Norris, G., Lee, S. G., Chun, O. K. & Blesso, C. N. Anthocyanin-rich 
black elderberry extract improves markers of HDL function and reduces aortic 
cholesterol in hyperlipidemic mice. Food Funct. 6, 1278–1287 (2015). 
114. Kotani, K., Yamada, T. & Gugliucci, A. Paired measurements of paraoxonase-1 
and serum amyloid A as useful disease markers. Biomed Res. Int. 2013, 1–4 
(2013). 
115. Çiftci, A. et al. Serum levels of nitrate, nitrite and advanced oxidation protein 
 105 
products (Aopp) in patients with nonalcoholic fatty liver disease. Acta 
Gastroenterol. Belg. 78, (2015). 
116. Zeisel, S. H., Klatt, K. C. & Caudill, M. A. Choline. Adv. Nutr. 9, 58–60 (2018). 
117. Shaw, G. M., Carmichael, S. L., Yang, W., Selvin, S. & Schaffer, D. M. 
Periconceptional dietary intake of choline and betaine and neural tube defects in 
offspring. Am. J. Epidemiol. 160, 102–109 (2004). 
118. Rees, W. D., Wilson, F. A. & Maloney, C. A. Sulfur Amino Acid Metabolism in 
Pregnancy: The Impact of Methionine in the Maternal Diet. J. Nutr. 136, 1701S–
1705 (2006). 
119. Zeisel, S. H. Requirements in Adults. 229–250 (2006). 
120. Fischer, L. M. et al. Sex and menopausal status influence human dietary 
requirements for the nutrient choline. Am J Clin Nutr 85, 1275–1285 (2007). 
121. Doles, C. D. et al. Dose and Timing of Prenatal Alcohol Exposure and Maternal 
Nutritional Supplements: Developmental Effects on 6-Month-Old Infants. Matern 
Child Heal. J. 19, 2605–2614 (2015). 
122. Weihrauch, J. L. & Son, Y. Phospholipid content of foods. J Am Oil Chem Soc 
1971–1978 (1983). doi:10.1007/BF02669968 
123. Zeisel, S. H., Mar, M.-H., Howe, J. C. & Holden, J. M. Concentrations of choline-
containing compounds and betaine in common foods. J. Nutr. 133, 1302–1307 
(2003). 
124. Fennema, D., Phillips, I. R. & Shephard, E. A. Minireview Trimethylamine and 
Trimethylamine N -Oxide , a Flavin-Containing Axis Implicated in Health and 
Disease. Drug Metab. Dispos. 070615, (2016). 
 106 
125. Kempson, S. A. & Montrose, M. H. Osmotic regulation of renal betaine transport: 
Transcription and beyond. Pflugers Arch. Eur. J. Physiol. 449, 227–234 (2004). 
126. Institute of Medicine, N. A. of S. U. Dietary reference intakes for folate, thiamin, 
riboflavin, niacin, vitamin B12, panthothenic acid, biotin, and choline. National 
Academy Press (1998). doi:10.1086/380067 
127. Lemos, B. S., Medina-Vera, I., Malysheva, O. V., Caudill, M. A. & Fernandez, M. 
L. Intake of Three Eggs/Day Increased Plasma Choline Without Increasing 
Plasma Trimethylamine-N-Oxide While Choline Supplementation had no Effect in 
These Parameters in a Young Population. J Am Coll Nutr (2018). 
128. Zeisel, S. H., Wishnok, J. S. & Blusztajn, J. K. Formation of Methylamines from 
Ingested Choline and Lecithin. J. Pharmacol. Exp. Ther. 225, 320–324 (1983). 
129. Warrier, M. et al. The TMAO-Generating Enzyme Flavin Monooxygenase 3 Is a 
Central Regulator of Report The TMAO-Generating Enzyme Flavin 
Monooxygenase 3 Is a Central Regulator of Cholesterol Balance. CellReports 10, 
326–338 (2015). 
130. Romano, K. A., Vivas, E. I., Amador-noguez, D. & Rey, F. E. Intestinal Microbiota 
Composition Modulates Choline Bioavailability. MBio 6, 1–8 (2015). 
131. Feller, A. G. & Rudman, D. Role of Carritine in Human Nutrition. J. Nutr. 118, 
541–547 (1988). 
132. Rebouche, C. J. & Chenard, C. A. Metabolic Fate of Dietary Carnitine in Human 
Adults: Identification and Quantification of urinary and Fecal Metabolites. J. Nutr. 
121, 539–546 (1991). 
133. Ey, J., Schömig, E. & Taubert, D. Dietary sources and antioxidant effects of 
 107 
ergothioneine. J. Agric. Food Chem. 55, 6466–6474 (2007). 
134. Zhang, A. Q., Mitchell, S. C. & Smith, R. L. Dietary precursors of trimethylamine in 
man: A pilot study. Food Chem. Toxicol. 37, 515–520 (1999). 
135. Mitchell, S. C., Zhang, A. Q. & Smith, R. L. Chemical and biological liberation of 
trimethylamine from foods. J. Food Compos. Anal. 15, 277–282 (2002). 
136. Chhibber-Goel, J. et al. The complex metabolism of trimethylamine in humans: 
endogenous and exogenous sources. Expert Rev. Mol. Med. 18, 1–11 (2016). 
137. Ufnal, M., Zadlo, A. & Ostaszewski, R. TMAO: A small molecule of great 
expectations. Nutrition 31, 1317–1323 (2015). 
138. Liao, Y.-T., Manson, A. C., DeLyser, M. R., Noid, W. G. & Cremer, P. S. 
Trimethylamine-N-oxide stabilizes proteins via a distinct mechanism compared 
with betaine and glycine. Proc. Natl. Acad. Sci. 114, 2479–2484 (2017). 
139. Velasquez, M. T., Ramezani, A., Manal, A. & Raj, D. S. Trimethylamine N-oxide: 
The good, the bad and the unknown. Toxins (Basel). 8, (2016). 
140. Schugar, R. C. & Brown, J. M. Emerging Roles of Flavin Monooxygenase 3 
(FMO3) in Cholesterol Metabolism and Atherosclerosis. Curr Opin Lipidol 33, 
395–401 (2015). 
141. Shih, D. M. et al. Flavin containing monooxygenase 3 exerts broad effects on 
glucose and lipid metabolism and atherosclerosis. J. Lipid Res. 56, (2015). 
142. Bennett, B. J., Vallim, T. Q. D. A., Wang, Z. & Shih, D. M. Trimethylamine-N-
Oxide, a Metabolite Associated with Atherosclerosis, Exhibits Complex Genetic 
and Dietary Regulation. 17, 49–60 (2014). 
143. Miao, J. et al. Flavin-containing monooxygenase 3 as a potential player in 
 108 
diabetes-associated atherosclerosis. Nat. Commun. 6, 6498 (2015). 
144. Mohammadi, A., Najar, A. G., Yaghoobi, M. M., Jahani, Y. & Vahabzadeh, Z. 
Trimethylamine-N-Oxide Treatment Induces Changes in the ATP-Binding 
Cassette Transporter A1 and Scavenger Receptor A1 in Murine Macrophage 
J774A.1 cells. Inflammation 39, 393–404 (2016). 
145. Miller, C. A. et al. Effect of egg ingestion on trimethylamine- N -oxide production in 
humans: a randomized, controlled, dose-response study. Am. J. Clin. Nutr. 100, 
778–786 (2014). 
146. Garner, S. C., Mar, M. H. & Zeisel, S. H. Choline distribution and metabolism in 
pregnant rats and fetuses are influenced by the choline content of the maternal 
diet. J. Nutr. 125, 2851–2858 (1995). 
147. Sheard, N. F. & Zeisel, S. H. An in vitro study of choline uptake by intestine from 
neonatal and adult rats. Pediatr. Res. 20, 768–772 (1986). 
148. Fernandez, M. L. & Webb, D. The LDL to HDL cholesterol ratio as a valuable tool 
to evaluate coronary heart disease risk. J Am Coll Nutr 27, 1–5 (2008). 
149. Friedewald, W. T., Levy, R. I. & Fredrickson, D. S. Estimation of the concentration 
of low-density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin. Chem. 18, 499–502 (1972). 
150. Levey, A. S. et al. Annals of Internal Medicine Article Using Standardized Serum 
Creatinine Values in the Modification of Diet in Renal Disease Study Equation for 
Estimating Glomerular Filtration Rate. Ann. Intern. Med. 145, 247–254 (2006). 
151. Board, A. E. Industry Overview - American Egg Board. Available at: 
http://www.aeb.org/farmers-and-marketers/industry-overview. (Accessed: 28th 
 109 
November 2017) 
152. Thiese, M. S. Observational and interventional study design types; an overview. 
Biochem. Medica 24, 199–210 (2014). 
153. Griffiths, K. et al. Food Antioxidants and Their Anti-Inflammatory Properties: A 
Potential Role in Cardiovascular Diseases and Cancer Prevention. Diseases 4, 
(2016). 
154. Salas-salva, J. O. et al. Reduction in the Incidence of Type 2 Diabetes With the 
Mediterranean Diet. Clin. Care/Education/Nutrition/Psychosocial Res. 34, 14–19 
(2011). 
155. Njike, V. Y., Ayettey, R. G., Rajebi, H., Treu, J. A. & Katz, D. L. Egg ingestion in 
adults with type 2 diabetes: effects on glycemic control, anthropometry, and diet 
quality—a randomized, controlled, crossover trial. BMJ Open Diabetes Res. Care 
4, (2016). 
156. Siri-Tarino, P. W., Sun, Q., Hu, F. B. & Krauss, R. M. Meta-analysis of prospective 
cohort studies evaluating the association of saturated fat with cardiovascular 
disease. Am J Clin Nutr 91, 535–46 (2010). 
157. Chowdhury, R. et al. Association of Dietary, Circulating, and Supplement Fatty 
Acids With Coronary Risk. Ann. Intern. Med. 160, 398 (2014). 
158. Forsythe, C. E. et al. Limited Effect of Dietary Saturated Fat on Plasma Saturated 
Fat in the Context of a Low Carbohydrate Diet. Lipids 45, 947–962 (2010). 
159. Hermsdorff, H. H. M., Zulet, M. A., Abete, I. & Martinez, J. A. A legume-based 
hypocaloric diet reduces proinflammatory status and improves metabolic features 
in overweight/obese subjects. Yale Law J. 50, 61–69 (2011). 
 110 
160. Visek, J., Lacigova, S., Cechurova, D. & Rusavy, Z. Comparison of a low-
glycemic index vs standard diabetic diet. Biomed Pap Med Fac Univ Palacky 
Olomouc Czech Repub 158, 112–116 (2014). 
161. Holscher, H. D. Dietary fiber and prebiotics and the gastrointestinal microbiota. 
Gut Microbes 8, 172–184 (2017). 
162. Koh, A., De Vadder, F., Kovatcheva-Datchary, P. & Bäckhed, F. From dietary 
fiber to host physiology: Short-chain fatty acids as key bacterial metabolites. Cell 
165, 1332–1345 (2016). 
163. Watson, R., DeMeester, F., Fernandez, M. & Andersen, C. Handbook of Eggs in 
Human Function, Human Health Handbooks. Biol. Fac. B. Gall. 9, (2015). 
164. Dietary Supplement Fact Sheet: Folate — Health Professional Fact Sheet. 
Available at: https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/. 
(Accessed: 28th November 2017) 
165. Abdel-Aal, E. S. M., Akhtar, H., Zaheer, K. & Ali, R. Dietary sources of lutein and 
zeaxanthin carotenoids and their role in eye health. Nutrients 5, 1169–1185 
(2013). 
166. Sun, G. et al. Gut microbial metabolite TMAO contributes to renal dysfunction in a 
mouse model of diet-induced obesity. Biochem. Biophys. Res. Commun. 493, 
964–970 (2017). 
167. Contreras-Zentella, M. L. & Hernández-Muñoz, R. Is Liver Enzyme Release 
Really Associated with Cell Necrosis Induced by Oxidant Stress? Oxid. Med. Cell. 
Longev. 2016, 1–12 (2016). 
168. Ghosh, G. C., Bhadra, R., Ghosh, R. K., Banerjee, K. & Gupta, A. RVX 208: A 
 111 
novel BET protein inhibitor, role as an inducer of apo A-I/HDL and beyond. 
Cardiovasc. Ther. 35, 1–10 (2017). 
169. Zhang, Y., Ma, K. L., Ruan, X. Z. & Liu, B. C. Dysregulation of the low-density 
lipoprotein receptor pathway is involved in lipid disorder-mediated organ injury. 
Int. J. Biol. Sci. 12, 569–579 (2016). 
170. Anderstam, B. et al. Modification of the oxidative stress biomarker AOPP assay: 
Application in uremic samples. Clin. Chim. Acta 393, 114–118 (2008). 
171. Livak, K. J. & Schmittgen, T. D. Analysis of Relative Gene Expression Data Using 
Real-Time Quantitative PCR and the 2−ΔΔCT Method. Methods 25, 402–408 
(2001). 
172. Wang, N., Silver, D. L., Costet, P. & Tall, A. R. Specific binding of ApoA-I, 
enhanced cholesterol efflux, and altered plasma membrane morphology in cells 
expressing ABC1. J. Biol. Chem. 275, 33053–33058 (2000). 
173. Mahley, R. W. Apolipoprotein E: from cardiovascular disease to 
neurodegenerative disorders. J. Mol. Med. 94, 739–746 (2016). 
174. Zheng, C. & Aikawa, M. High-density lipoproteins: From function to therapy. J. 
Am. Coll. Cardiol. 60, 2380–2383 (2012). 
175. März, W. et al. HDL cholesterol: reappraisal of its clinical relevance. Clin. Res. 
Cardiol. 106, 663–675 (2017). 
176. Kim, D. S. et al. Dietary cholesterol increases paraoxonase 1 enzyme activity. J. 
Lipid Res. 53, 2450–2458 (2012). 
177. Ozenirler, S. et al. The relationship between advanced oxidation protein products 
(AOPP) and biochemical and histopathological findings in patients with 
 112 
nonalcoholic steatohepatitis. J. Dig. Dis. 15, 131–136 (2014). 
178. Horton, J. D., Goldstein, J. L. & Brown, M. S. SREBPs : activators of the complete 
program of cholesterol and fatty acid synthesis in the liver. 109, 1125–1131 
(2002). 
179. Wong, J., Quinn, C. M. & Brown, A. J. SREBP-2 positively regulates transcription 
of the cholesterol efflux gene , ABCA1 , by generating oxysterol ligands for LXR. 
491, 485–491 (2006). 
180. RobinsonCohen, C. et al. Association of FMO3 Variants and Trimethylamine 
NOxide Concentration, Disease Progression, and Mortality in CKD Patients. PLoS 
One 1–11 (2016). doi:10.1371/journal.pone.0161074 
181. Holm, P. I., Ueland, P. M., Kvalheim, G. & Lien, E. A. Determination of choline, 
betaine, and dimethylglycine in plasma by a high-throughput method based on 
normal-phase chromatography-tandem mass spectrometry. Clin. Chem. 49, 286–
294 (2003). 
182. Yan, J. et al. Maternal choline intake modulates maternal and fetal biomarkers of 
choline metabolism in humans. Am. J. Clin. Nutr. 95, 1060–1071 (2012). 
183. Olthof, M. R., Brink, E. J., Katan, M. B. & Verhoef, P. Choline supplemented as 
phosphatidylcholine decreases fasting and post-methionine plasma homocysteine 
concentrations in healthy men. Am J Clin Nutr 82, 111–117 (2005). 
184. Blusztajn, J. K. Choline, a Vital Amine. Science (80-. ). 281, 794 LP-795 (1998). 
185. Hazen, S. L. & Brown, J. M. Eggs as a dietary source for gut microbial production 
of trimethylamine-N-oxide. Am. J. Clin. Nutr. 100, 741–743 (2014). 
186. Zierenberg, O. & Grundy, S. M. Intestinal absorption of 
 113 
polyenephosphatidylcholine in man. Jouranl Lipid Res. 23, 1136–1142 (1982). 
187. Mueller, D. M. et al. Plasma levels of trimethylamine-N-oxide are confounded by 
impaired kidney function and poor metabolic control. Atherosclerosis 243, 638–
644 (2015). 
188. West, A. A. et al. Egg n-3 Fatty Acid Composition Modulates Biomarkers of 
Choline Metabolism in Free-Living Lacto-Ovo-Vegetarian Women of Reproductive 
Age. J. Acad. Nutr. Diet. 114, 1594–1600 (2014). 
189. Naidoo, A., Naidoo, K., Yende-zuma, N. & Gengiah, T. N. Gut Microbiota-
Dependent Trimethylamine N-oxide (TMAO) Pathway Contributes to Both 
Development of Renal Insufficiency and Mortality Risk in Chronic Kidney Disease. 
Circ. Res. 19, 161–169 (2015). 
 
 
 
 
 
 
 
 
 
 
 
 
 114 
 
